Press Release Communiqué de presse - September 20, 2006 20 September, 2006

Diabetic Product Development Leads to Name Change: Sernova Corp.

Kelowna, B.C. - Pheromone Sciences Corp. is pleased to announce it has changed its name to Sernova Corp. ("Sernova"). The company's new stock symbol is SVA.

"The new name fits better with projects such as our current development of a potential breakthrough treatment for diabetes," said Chairman Dr. William Cochrane. "We wanted a new name to help make it clear to investors that our focus is no longer centred around pheromones, but can include all kinds of biotechnology developments."

Shareholders approved the name change at the Company's annual general meeting held on August 18th 2006 and elected 5 directors to the Board: Dr. William Cochrane (Chair), Charles Allard, Justin Leushner, Devinder Randhawa and Dr. Eldon Smith.

The Company's officers are: Chief Executive Officer- Devinder Randhawa, President-Justin Leushner, and Chief Financial Officer and Corporate Secretary-Patrick Groening.

Sernova Corp. is a biotechnology research and development company focused on commercializing medical technologies.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, CEO

For further information contact: TEL: (888) 318-7062 Mr. Phil Morehouse FAX: (250) 868-8493 Sernova Corp.

Press Release Communiqué de presse - April 28, 2009 28 April, 2009

New Strategic Plan

APPOINTMENT OF DR. PHILIP TOLEIKIS AS PRESIDENT AND CEO * PRIVATE PLACEMENT FINANCING * GRANT OF STOCK OPTIONS

London, Ontario - April 28, 2009 - Sernova Corp. (TSX-V: SVA)

At the Annual General Meeting of Shareholders held today, the Sernova Board of Directors issued its report on the internal review of the Corporation's research and development, financing and partnering activities and strategies that had been conducted over the last three months by Mr. Jeffrey Bacha, an independent Director of the Corporation. Based on the analysis of the Corporation's scientific progress to date, regulatory requirements, and financial and human resources, the Board of Directors has approved Mr. Bacha's recommended strategic plan.

Sernova's immediate priority will be to seek scientific collaborations with key international transplant centres that currently offer islet transplantation (known as the Edmonton Protocol) to patients suffering from Type 1 diabetes. Sernova strongly believes that its proprietary Sertolin(tm) technology, which utilizes co- transplantation of porcine islets and Sertoli cells in a unique transplantation device, offers a quantum leap forward over the Edmonton Protocol, the current standard of care. The limitations of the Edmonton Protocol are well understood: very small source of donated human islets, potential damage to the patient's liver, significant loss of islets following transplantation, severe immune and inflammatory responses to the transplanted islets, and the permanent need for the patient to take toxic and expensive anti- rejection drugs. The Sertolin(tm) treatment would potentially overcome all of the Edmonton Protocol limitations in a simpler, less invasive, safer and less expensive way, since it is based on the availability of a large supply of porcine islets and sertoli cells from controlled herds, reduced loss of islets following transplantation, no minimal immune or inflammatory responses, and no need for any antirejection drugs.

Sernova has already initiated discussions with several key transplantation centres in the United States with a view to establishing scientific collaborations to demonstrate proof of concept and commercialize Sertolin(tm). Mr. Bacha stated: "By working together with leading transplant centres, we can achieve far more in a shorter period of time, and ensure the highest quality studies that will meet the standards of the FDA and the international scientific community."

Sernova is also aggressively seeking government and private grants to fund key projects within the overall Sertolin(tm) development plan. Until further funding and/or scientific collaborations are secured, the Corporation has significantly reduced its overhead and operating expenses.

The Board of Directors also announces the appointment of Dr. Philip Toleikis as the President and CEO of the Corporation. Dr. Toleikis is a seasoned and experienced biotechnology executive, with over 20 years of research, intellectual property, management and business experience in the pharmacology and biotechnology sectors. His most recent position was as Vice President, R&D Pharmacology and Drug Screening, for Angiotech Pharmaceuticals, Inc. of Vancouver, British Columbia, where he built a major scientific and information technology team that included senior scientists, research scientists and technicians. Dr. Toleikis' major achievements at Angiotech included successful completion of Phase II European Clinical Trials, chairing the Joint Research Committee, in-licensing and out- licensing of technologies, and management of key patents and patent applications. Dr. Toleikis is the author of multiple issued patents and over 110 patent applications. His research training and experience includes biochemical pharmacology, diabetes, oncology, inflammatory diseases (psoriasis, multiple sclerosis, surgical adhesions, Alzheimer's disease and rheumatoid arthritis), osteoarthritis, neurological diseases and cardiovascular conditions including ischemic heart disease, cardiomyopathy, hypertension and aneurysms. Dr. Toleikis will be presenting on the Corporation's behalf at the BioFinance Conference in Toronto on Wednesday, April 29, 2009.

Dr. George Adams, Chairman of the Board of Directors, welcomed Dr. Toleikis, stating "Sernova is privileged to now be led by such a distinguished scientist and executive. We are fully confident that Dr. Toleikis will drive our technology through the worldwide regulatory process and into commercialization. The treatment of insulin- dependent diabetes will be just the first commercial application of our platform technology. On behalf of the Board of Directors and our shareholders, I welcome Dr. Toleikis to the Sernova family."

Sernova also announces that it will be seeking the approval of the TSX Venture Exchange for a private placement of up to 14 million shares at a price of $0.03 per common share, for aggregate consideration of $420,000. A commission of 10%, along with a 10% agents warrant to purchase common shares at $0.05 per common share, will be paid.

The Corporation also announces the granting of incentive stock options to an officer to purchase up to 700,000 common shares at $0.10 per share for a period of 5 years expiring April 28, 2014.

About Sernova Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

For further information contact: Craig Gauld, Executive Vice President Tel: (888) 318-7062; (519) 858-5126 info@sernova.com www.sernova.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE

Press Release Communiqué de presse - July 12, 2010 12 July, 2010

Sernova Announces Positive Results of its Proprietary Cell Pouch System(tm) in Preclinical Diabetes Model

Source: Sernova Corp

July 12, 2010, 6:00 a.m. EDT

LONDON, ONTARIO--(Marketwire -- July 12, 2010) - Sernova Corp. (TSX VENTURE:SVA) is pleased to report positive results from a long-term study evaluating the safety and efficacy of the Cell Pouch System(TM) in a pre- clinical model of diabetes.

Detailed data will be presented at the 23rd International Conference of the Transplant Society, Vancouver, British Columbia, Canada, August 15th-19th in a presentation entitled, "A novel Cell Pouch(TM), an alternative to intrahepatic islet transplantation."

Dr. Philip Toleikis, Sernova's President & CEO, noted "Our Cell Pouch System(TM) is a proprietary medical device implanted under the skin rapidly forming into a tissue- engineered, organ-like structure that provides a natural environment for the survival and function of therapeutic cells. These long-term results represent a significant achievement as a possible alternative to the current practice of injecting islets directly into the portal vein of the liver."

"Our data are profound because they suggest the potential to reduce side-effects associated with the current standard of care and achieve glucose control with significantly fewer islets than normally required," said Toleikis.

On March 16, 2010, Sernova reported initial results demonstrating that the Cell Pouch System(TM) becomes rapidly vascularised and achieved initial glucose control in subject animals.

The following summarizes important new findings reported today: Long-term insulin independence was successfully achieved with significantly fewer islets than the current standard of care, requiring only about 10% of insulin- producing islets normally used for the Edmonton Protocol. Animals in the study achieved long-term glucose normalization throughout the course of the study. Standard laboratory tests demonstrated transplanted islets produced insulin and responded similarly to non- diabetic animals to provide control of glucose. No adverse events related to the Cell Pouch System(TM) occurred during the study. About the Study

The Cell Pouch System(TM) was implanted in pigs which were then made diabetic through removing the pancreas and chemical induction. The animal's own islets (Autograft) isolated from the pancreas were transplanted into the device. Standard measures of efficacy including fasting and non-fasting glucose levels, glucose tolerance tests (IVGTT), and C-peptide were taken up to 72 days post- transplant. At the end of the study period, the device containing the islets was removed and the animals returned to a diabetic state.

Following transplantation, a substantial number of study animals maintained glucose levels within the normal range, showed glucose tolerance tests (IVGTT) similar to non-diabetic animals and were C-peptide positive, an important confirmation of insulin-producing islet function. Microscopic fluorescence analysis of the device revealed both microvessels and insulin associated with islets.

Upon removal of the Cell Pouch System(TM) containing islets, fasting glucose levels returned to the diabetic range and animals required daily insulin injections to maintain normal glucose levels. The animals return to the diabetic state was further confirmed by IVGTT and C- peptide analysis.

From a safety perspective, no adverse events occurred related to the Cell Pouch(TM) throughout the study following implantation of over 40 devices for up to 5 months. The devices were well-incorporated with collagen at all time points and yet were not visible under the skin, an important consideration for patients.

Dr. David White, Chair of Sernova's Scientific Advisory Board stated, "I am particularly enthusiastic about these results and the potential clinical relevance to patients suffering from diabetes. These new data suggest that the Cell Pouch System(TM) represent a possible clinically relevant alternative to injection of islets into the portal vein of the liver and may reduce the side effects of transplantation including the instant blood- mediated reaction (IBMR). The indication that our device achieves glucose control with a reduction in the number of islets normally required is also of profound clinical importance as it may increase the availability of life-changing islet transplantation to many diabetic patients."

Sernova believes that the Cell Pouch System(TM) has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, and other chronic debilitating diseases. Based on these encouraging results, the Company is taking steps towards clinical evaluation of its Cell Pouch System(TM).

According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every eight dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities - that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - March 03, 2011 3 March, 2011

Sernova To Present Cell Pouch System™ Research Results At Transplantation Conference

Source: Sernova Corp

FOR RELEASE

March 3, 2011, 6:00 a.m. EST

LONDON, ONTARIO--(Marketwire - March 3, 2011) - Sernova Corp. (TSX VENTURE:SVA) is pleased to announce the Company will present results of preclinical studies with its Cell Pouch System(TM), at the Canadian Society of Transplantation 2011 Annual Scientific Conference at Mt-Tremblant, Quebec, Canada held March 2-5.

The conference brings together eminent scientists and clinicians in the cell and organ transplantation field from across Canada and around the world. Sernova will be making three poster presentations entitled:

"The establishment of a stringent large animal model of insulin-dependent diabetes"

"A subcutaneous Cell Pouch(TM) as an alternative to intraportal infusion of islets of Langerhans to restore carbohydrate control in the diabetic recipient," and

"Islets transplanted into a subcutaneous Cell Pouch(TM) demonstrate long-term efficacy measured by C- peptide."

"The conference provides a venue to discuss the attributes of Sernova's novel Cell Pouch System(TM) as an alternate site for insulin-producing islet transplantation and its potential for additional cellular therapies with leaders from the medical transplantation community," stated Delfina Siroen, Sernova's Research and Development Head.

The Cell Pouch System(TM) is a proprietary medical device which may offer a revolutionary improvement over the current practice of injecting therapeutic cells into blood vessels. Based on previous pre-clinical research, the Cell Pouch System(TM) becomes a vascularised organ-like endocrine structure when placed in the body, providing the microcirculation thought to be essential to early function and long-term survival of therapeutic cells. Sernova has conducted efficacy studies in small and large animal models of diabetes and shown the device with insulin-producing islets to control blood glucose levels long-term without the need for daily insulin injections. Sernova believes the Cell Pouch System(TM) has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases.

According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - October 25, 2011 25 October, 2011

Sernova Enters Into Collaboration With Edmonton's Clinical Islet Transplant Program To Expand Cell Pouch(tm) Applications For Diabetes Treatment

Source: Sernova Corp

LONDON, ONTARIO - (Marketwire - October 25, 2011) - Sernova Corp. (TSX-V: SVA), is pleased to announce it has entered into a collaboration with The Clinical Islet Transplant Program at the University of Alberta Hospital.

The Program is headed by Dr. James Shapiro, MD, Ph.D. FRCS (Eng) FRCSC, the leader of the team that developed the Edmonton Protocol, the current standard of care for islet transplantation. In September 2010, following review of Sernova's preclinical data, Dr. Shapiro joined the Corporation's Scientific Advisory Board.

"Dr. Shapiro's contributions to date position us to enter into this important collaboration which is targeted to expand access to islet transplantation for the treatment of diabetes to a much wider base of patients using Sernova's Cell Pouch(tm)," said Dr. Philip Toleikis, Ph.D., President and CEO of Sernova.

The current procedure for islet transplantation to treat diabetes, commonly known as the "Edmonton Protocol" involves transplanting islets directly into a blood vessel (portal vein) of the liver. The Cell Pouch(tm) is expected to solve a number of issues arising from portal vein delivery. For example, the Cell Pouch(tm) provides a natural setting where blood vessels grow adjacent to the islets rather than being bathed in blood which can result in the death of up to 75% of the islets through an instant blood mediated inflammatory response (IBMIR). Use of the Cell Pouch(tm) would eliminate portal vein hypertension and thrombosis associated with portal vein islet delivery and potentially reduce the cost of the procedure as the catheterization laboratory is not required for implantation of the Cell Pouch(tm) or islet transplantation. Importantly, preclinical studies of the Cell Pouch(tm) have consistently shown excellent safety and efficacy profiles with significantly fewer islets than for portal vein delivery, which could increase the number of recipients treated with the current donor pool. Furthermore, implantation of the Cell Pouch(tm) just under the skin allows for imaging of the islets and microvessels and for local immunoprotection of therapeutic cells.

Sernova's Cell Pouch(tm) is a scalable medical device providing a natural "organ-like" environment for therapeutic cells. Once implanted under the skin, the Cell Pouch(tm) develops pancreas-like function when infused with islets, controlling blood sugar levels as shown by published preclinical data which also suggests that the natural environment promotes cell survival reducing the number of islets required for therapy.

Sernova is currently pursuing upcoming human testing of the Cell Pouch(tm) based on the strong preclinical safety and efficacy data generated to date.

This collaboration will further seek to position the Cell Pouch(tm) through next generation improvements to the Edmonton Protocol to expand access to cell transplant to a much wider patient population. The collaboration will include work related to: Assessment of islet protective agents that could further reduce the islet mass required for each transplant using the Cell Pouch(tm)

Assessment of locally administered anti-rejection strategies within the Cell Pouch(tm) with the goal of reducing or eliminating systemic antirejection regimens

Assessment of a proprietary, ethically derived insulin- producing stem cell technology within the Cell Pouch(tm) as an enabling technology which could significantly expand the number of patients treated

Development of high resolution imaging systems to enable physicians to better assess and optimize long- term islet function A video describing the Edmonton Protocol and the collaboration of Sernova with Dr. Shapiro may be viewed on Sernova's website at www.sernova.com

"The safety and efficacy of the Cell Pouch(tm) in preclinical studies is impressive. We are excited to be working with Sernova in both preparing for its upcoming clinical trial and in this collaboration. We are hopeful that Sernova's Cell Pouch(tm) will significantly increase the number of diabetic patients that can be treated with islet transplantation," said Dr. Shapiro, Director of the Clinical Islet Transplant Program, at the University of Alberta and member of Sernova's Scientific Advisory Board.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities - that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - May 02, 2012 2 May, 2012

Sernova Receives Health Canada Approval to Initiate Human Clinical Trials of its Cell Pouch ™

-Patients with insulin-dependent diabetes to be treated with Sernova's subcutaneous Cell Pouch (TM) and insulin- producing islets-

Source: Sernova Corp

LONDON, ONTARIO--(Marketwire - May 2, 2012) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA - News) today announced it received Health Canada Approval to conduct a human clinical trial assessing both the safety and efficacy of Sernova's Cell Pouch(TM) with transplanted insulin-producing islets in patients with insulin-dependent diabetes. The study will be conducted in collaboration with Dr. James Shapiro at the University of Alberta Health Science Centre in Edmonton.

"Sernova's compelling pre-clinical results provide optimism that the Cell Pouch(TM) has the potential to change the standard of care of patients with diabetes receiving islet transplantation," said Dr. James Shapiro, principal investigator of the study. "I am excited to begin enrolment of patients in this ground breaking clinical study to evaluate the Cell Pouch(TM) in humans."

The study, entitled "A Phase I/II Study of the Safety and Efficacy of Sernova's Cell Pouch(TM) for Therapeutic Islet Transplantation," is an open label, non- randomized, single-arm, Phase I/II safety and efficacy study of up to 20 patients with insulin-dependent diabetes undergoing allograft pancreatic islet transplantation.

In this study, patients who have met the enrolment criteria and provided informed consent will be implanted with the Cell Pouch(TM) approximately 2-12 weeks prior to transplantation of donor human islets. To prevent islet graft rejection, patients will be treated with the standard immunosuppressive regimen.

The primary endpoint of the study is to assess the safety of the Sernova Cell Pouch(TM) in adult participants with Type-1 diabetes receiving islet transplantation for the first time. This endpoint will be assessed just prior to islet transplantation and one month thereafter.

The secondary endpoint of the study is to determine the proportion of subjects implanted with the Cell Pouch(TM) and transplanted with islets who achieve and maintain insulin independence as measured three months post-final islet transplantation.

In addition, the study will provide preliminary data on the efficacy of the Cell Pouch(TM) to maintain adequate immunological protection against both allo- and autoimmunity of islet transplant recipients.

Following assessment of primary and secondary endpoints, patients will be followed for a minimum of three years to assess long-term safety and efficacy of the Cell Pouch(TM). It should also be noted that the study allows for interim analysis of the data at various study time points.

"The initiation of this study marks a significant milestone for Sernova, and is the result of years of hard work and dedication from our company's staff and collaborators," said Dr. Philip Toleikis, President and CEO of Sernova Corp. "We have developed the subcutaneous Cell Pouch(TM) for Sernova's first clinical application, insulin- dependent diabetes, as an alternative site for islet transplantation that may allow for safer, more efficient engraftment of islets and potential improved long-term insulin independence using a marginal islet mass. We are pleased to have Dr. Shapiro and his team conduct this study at this world class institute for islet transplantation."

The Cell Pouch(TM) is a proprietary medical device that, once implanted subcutaneously, incorporates with tissue and microvessels. It has been shown in multiple preclinical studies to provide a safe environment for transplantation, as well as long-term survival and efficacy of therapeutic cells. Sernova's goals for the diabetes indication include making the Cell Pouch(TM) available to a wider group of patients than currently possible with intraportal delivery of islets. Sernova also plans to make the Cell Pouch(TM) available as a natural, improved site for non- primary- derived, insulin-secreting cells for long-term function to enable large numbers of patients with insulin- dependent diabetes to be treated without limitation to availability of cells.

About Sernova

Sernova Corp. is a clinical stage health-sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin-dependent diabetes, using the novel Cell Pouch System(TM) for transplantation and long- term survival of therapeutic cells and its patented Sertolin(TM) cell technology which can provide an immune-protected local environment for therapeutic cells.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward- looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Press Release Communiqué de presse - August 15, 2012 15 August, 2012

World First - Islet Transplant Into Man Using Sernova's Cell Pouch™ For Treatment Of Diabetes

-Company to Host Conference Call at 9 a.m. EDT, Today, Aug. 16, to Discuss Clinical and Business Developments-

Source: Sernova Corp

LONDON, ONTARIO and EDMONTON, ALBERTA (Marketwire -- August 16, 2012) -- Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA - News) and the University of Alberta today announced the treatment of the first patient with insulin- producing islets transplanted into Sernova's Cell Pouch(TM) in a Phase I/II clinical study to treat Type-1 diabetes led by Dr. James Shapiro, Professor of Surgery and Medicine, University of Alberta and Director, Clinical Islet Transplant Program. Sernova will host a conference call at 9 a.m. EDT, today, Aug. 16, 2012, to discuss the company's clinical and business developments.

"The Sernova Cell Pouch(TM) implantation and transplantation processes are simple, rapid minimally invasive procedures, conducted on an outpatient basis under local anesthesia," said Dr. Shapiro. "This offers substantial potential benefit over the Edmonton protocol and the ease of use provides an opportunity for the Cell Pouch(TM) to become the standard of care for people with diabetes if it proves to be effective in these initial trials."

The objectives of the human clinical trial are to assess the safety and efficacy of the Cell Pouch(TM) with transplanted islets in up to 20 patients with Type- 1 diabetes. The study is sponsored by Sernova Corp and the University of Alberta. In the study, patients who have met the enrolment criteria and provided informed consent are implanted with the Cell Pouch(TM) prior to transplantation of donor human islets. To prevent islet graft rejection, patients in this study are treated with the best in class standard of care immunosuppression protocol. Interim analysis of the data from this clinical study is expected during H1, 2013. Further information on the trial may be found at www.clinicaltrials.gov (Identifier: NCT01652911).

"The Cell Pouch(TM) is a breakthrough technology which has the potential to significantly improve the lives of people living with chronic diseases such as diabetes," said Philip Toleikis, Ph.D., President and CEO of Sernova Corp. "Supported by Sernova's strong preclinical results, the treatment of patients in this clinical trial of the Cell Pouch(TM) further advances our vision for the future of providing millions of diabetic patients with the Cell Pouch(TM), and an unlimited source of insulin- producing cells protected with a local anti-rejection technology."

Conference Call

The conference call to discuss Sernova's clinical and business developments may be accessed by dialing 866- 532-1852 for domestic callers and +443-842- 7644 for international callers. Please specify to the operator that you would like to join the "Sernova conference call" or "conference ID: 21155379."

About The Cell Pouch(TM)

The Cell Pouch(TM) is a proprietary medical device that, following subcutaneous implantation, incorporates with tissue and microvessels forming a natural environment for transplantation of therapeutic cells. Multiple preclinical studies demonstrated the Cell Pouch(TM) to provide a safe environment for transplantation, as well as long- term efficacy of therapeutic cells. Sernova's goals for the Cell Pouch(TM) for diabetes include providing a safe and natural site for islets to significantly increase the number of patients currently treated with intraportal delivery of donor islets and to provide a safe environment for virtually unlimited available sources of insulin-secreting cells such as insulin-producing stem cells and xenogeneic cells. This vision combined with local anti-rejection protection of the cells could enable millions of patients with insulin- dependent diabetes to be treated without limitation to availability of cells.

About Sernova

Sernova Corp. is a clinical stage health-sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin-dependent diabetes, using the novel Cell Pouch System(TM) for transplantation and long- term survival of therapeutic cells and its patented Sertolin(TM) cell technology which can provide an immune-protected local environment for therapeutic cells.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Dr. James Shapiro MD PhD FRCS Professor of Surgery and Medicine, University of Alberta Director, Clinical Islet Transplant Program Tel: (780) 407-7330

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward- looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Press Release Communiqué de presse - February 28, 2013 28 February, 2013

Sernova and Centre for Commercialization of Regenerative Medicine Partner To Treat Chronic Diseases

February 28, 2013 (TORONTO and LONDON, ON) -- The Centre for Commercialization of Regenerative Medicine (CCRM) is pleased to announce the addition of Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA - News) to its member-based industry consortium. Sernova's combination of immuno-protective technology and therapeutic cells for the treatment of chronic diseases advances CCRM's goal of developing innovative cell- based product.

"Sernova's technology for transplanting therapeutic cells into an implanted medical device for the treatment of diabetes and other chronic diseases goes hand- in-hand with our strategy of translating cell-based medical discoveries into commercial products and therapies," says Dr. Michael May, CEO of CCRM. "Sernova's expertise in the area of cell therapy will bring great value to CCRM's core development platforms and to other consortium members."

CCRM is working with its industry consortium to address real-life bottlenecks in cell-based product pipelines. Its industry consortium now numbers over 20 members. These companies represent the key sectors of the industry: therapeutics, devices, reagents, and cells as tools.

"Becoming a member of CCRM offers the opportunity for further validation for our technology and demonstrates our company's commitment to the advancement of our Cell Pouch System(tm) as an effective, safe, long- term and convenient therapeutic option for the treatment of chronic diseases," says Dr. Philip Toleikis, President and CEO of Sernova Corp. "We will work together with the other consortium members to achieve CCRM's objectives in treating and managing devastating diseases such as diabetes."

CCRM has built three core development platforms: cell reprogramming and engineering; cell manufacturing; and, biomaterials and devices to carry out projects commissioned by academia and industry. CCRM has a fully resourced, 6,000 square foot development facility where all development work takes place.

Please visit www.ccrm.ca/industry-consortium to see a complete list of CCRM's members.

About the Centre for Commercialization of Regenerative Medicine (CCRM) CCRM, a Canadian not-for-profit organization funded by the Government of Canada's Networks of Centres of Excellence program and six academic partners, supports the development of technologies that accelerate the commercialization of stem cell- and biomaterials- based technologies and therapies. A network of academics, industry and entrepreneurs, CCRM aims to translate scientific discoveries into marketable products for patients. CCRM launched in Toronto's Discovery District on June 14, 2011.

About Sernova Sernova Corp. is a clinical stage health-sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin-dependent diabetes, using the novel Cell Pouch System(TM) for transplantation and long- term survival of therapeutic cells and its patented Sertolin(TM) cell technology, which can provide an immune-protected local environment for therapeutic cells.

For more information on CCRM, please contact: Stacey Johnson Manager, Communications Centre for Commercialization of Regenerative Medicine 647-309-1830 stacey.johnson@ccrm.ca www.ccrm.ca

For further information on Sernova, please contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Press Release Communiqué de presse - September 09, 2013 9 September, 2013

Sernova And Medicyte To Collaborate On Cell-Based Therapy To Treat Haemophilia

* Novel Approach to Address Unmet Need for an Effective Therapy *

LONDON, ONTARIO and HEIDELBERG, GERMANY-- (Marketwire -- September 10, 2013) - Sernova Corp. (TSX- V: SVA) and Medicyte GmbH, today announced that the companies have entered into a Material Transfer Agreement (MTA) to jointly evaluate the use of Medicyte's upcyte® cells in Sernova's Cell Pouch(TM) for the treatment of patients with haemophilia A.

The two companies have also entered into a nonbinding term sheet outlining the general terms of a collaboration for the pre-clinical and clinical development of the novel Cell Pouch(TM)/upcyte® combination product for the treatment of haemophilia A. The parties intend to complete negotiations of a definitive agreement while initial research is being carried out under the terms of the MTA.

"The joint development program with Medicyte is further indication that our Cell Pouch(TM) technology is versatile and has high potential to be employed for the treatment of a range of chronic diseases," said Dr. Philip Toleikis, President and CEO Sernova Corp. "We are in line with our strategy to expand the testing of the Cell Pouch(TM) in various indications by collaborating with leading cell-based therapy companies, such as Medicyte."

Dr. Joris Braspenning, CEO of Medicyte, added, "There is a great unmet medical need for the treatment of severe haemophilia A. We believe that Medicyte's upcyte® cells being sheltered in Sernova's Cell Pouch(TM) represent a promising combination of technologies to produce effective levels of Factor VIII, and to prevent excessive bleeding episodes of patients suffering haemophilia A. Together with Sernova, we are looking forward to evaluating the potential of a combined product."

Haemophilia A is the most common form of haemophilia and results from a deficiency of clotting Factor VIII to a level of less than 1% of the normal blood concentration. Haemophiliacs have prolonged bleeding which in areas such as the brain can be fatal or inside joints can be permanently debilitating. Approximately 20,000 people in the United States have the moderate or severe form of haemophilia A, as well as approximately 2,500 in Canada and 10,000 in Europe. Though there is no cure for haemophilia A, it is currently controlled with regular injections of recombinant clotting Factor VIII. Annual costs for the treatment of the disease may range from $60,000 to $260,000 per patient for a total cost of between $2-4B per year in North America and Europe.

Development of a product capable of producing an effective level of Factor VIII within the Cell Pouch(TM) environment has the potential to provide haemophilia A patients with better protection against dangerous episodes of excessive bleeding and greatly reduce annual therapy costs.

Continuation of the parties' joint studies beyond the MTA is subject to negotiation and execution of a definitive collaboration agreement.

About Medicyte

Medicyte is specialised in the controlled generation and standardisation of human primary cell products in virtually unlimited quantities and of highest quality for cell therapy and cell-based R&D. Medicyte's proprietary technologies upcyte® and vericyte® enable researchers to expand human cells from different donors and from multiple tissues in a standardized procedure, thereby making these cells for the first time commercially available in high numbers and consistent quality. Beside their therapeutic applications, pharmaceutical companies are using upcyte® and vericyte® products for in vitro assays and ADMET testing.

For further information contact: Joris Braspenning, Ph.D., CEO Tel: +49 (6221) 72925-30 j.braspenning@medicyte.com www.medicyte.com

About Sernova Sernova Corp. is a clinical stage health-sciences company focused on commercializing medical technologies. Sernova is developing a platform technology based on the Cell Pouch(TM), Sertolin(TM) and therapeutic cells, for a number of chronic diseases, including insulin-dependent diabetes as a first indication and other cell therapies for diseases such as parathyroid disease, haemophilia, and Parkinson's disease. Sernova's goals for the Cell Pouch(TM) for diabetes include increasing the number of patients currently treated with intraportal delivery of donor islets and to provide a safe environment for sources of unlimited insulin-secreting cells such as insulin-producing stem cells and xenogeneic cells. This vision combined with local anti-rejection protection of the cells could enable millions of patients with insulin-dependent diabetes to be treated without limitation to availability of cells.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - April 21, 2014 21 April, 2014

Sernova’s Cell Pouch™ Diabetes Clinical Trial Demonstrates Interim Safety and Biocompatibility

Sernova’s Cell Pouch with insulin-producing islets is safe and biocompatible in patients with unstable diabetes

Source: Sernova Corp FOR RELEASE April 22nd, 2014, 6:00 a.m. EDT LONDON, ONTARIO--(Marketwire – April 22nd, 2014) - Sernova Corp. (TSX-V: SVA), a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases, today announced interim results in an ongoing type 1 diabetes human clinical trial with the Company’s Cell Pouch(TM).

Sernova’s human clinical trial is designed to assess the safety and efficacy of the Cell Pouch in subjects with unstable diabetes receiving an islet transplant. Interim study results in the first group of patients support that the implanted Cell Pouch, transplanted with insulin-producing islets is showing longer-term safety and biocompatibility with one of the patients beyond the 180 day time point.

Encouraging early results up to 30 days post-islet transplant were presented at the International Pancreas and Islet Transplantation Congress in September, 2013. These results showed after implantation under the skin, the Cell Pouch is safe and biocompatible. Following islet transplantation, the islets living within a natural tissue matrix were supported with a rich supply of blood vessels, similar to the pancreas. Of further importance, the islets were shown to make insulin, somatostatin and glucagon – key hormones in the control of blood sugar levels. The ongoing study is being conducted with Dr. James Shapiro as principal investigator at the University of Alberta Health Sciences Centre in Edmonton, Alberta.

"The fact that the Cell Pouch continues to exhibit both safety and biocompatibility in longer term follow-up is an important milestone in the early clinical testing of this device, and provides encouragement that human islets transplanted within the device may provide the opportunity to change the standard of care of patients with diabetes," said Dr. James Shapiro. “I look forward to the ongoing results of the investigation as the study progresses."

The study, entitled “A Phase I/II Study of the Safety and Efficacy of Sernova's Cell Pouch for Therapeutic Islet Transplantation,” is an open label, non- randomized, Phase I/II safety and efficacy study of up to 20 patients with type 1 diabetes undergoing allograft pancreatic islet transplantation. Patients who have met the enrolment criteria and provided informed consent are implanted with the Cell Pouch approximately 2-24 weeks prior to transplantation of donor human islets. To prevent islet graft rejection, the standard of care immunosuppressive regimen is provided.

The primary endpoint of the study is to assess the safety of the Sernova Cell Pouch in these patients just prior to islet transplantation, following islet transplantation and at various points during follow up. The secondary endpoint of the study, efficacy, is to determine the proportion of subjects implanted with the Cell Pouch and transplanted with islets who achieve and maintain insulin independence. Patient follow up occurs for a minimum of three years to assess long-term safety and efficacy.

“In the second half of 2014, we expect to provide further preliminary safety and efficacy data”, remarked Dr. James Shapiro.

"This interim update by Dr. Shapiro suggests we are making positive strides forward. The Cell Pouch could potentially be a game changer for patients suffering from this debilitating disease. Indeed, this is the result of years of hard work and dedication from our company's staff and collaborators," said Dr. Philip Toleikis, President and CEO of Sernova Corp. "We have developed the subcutaneous Cell Pouch for Sernova's first clinical application, insulin- dependent diabetes, as an alternative site for islet transplantation that may allow for safer, more efficient engraftment of islets and potential improved long-term insulin independence using a marginal islet mass. What adds further credence to the Cell Pouch’s mechanism of action is the application of the Cell Pouch for other clinical indications which Sernova is undertaking”, added Dr. Toleikis."

About the Cell Pouch The Cell Pouch is a proprietary, scalable, biocompatible medical device, that once implanted subcutaneously, incorporates with the patient’s tissue and microvessels. The Cell Pouch is contract manufactured (ISO13485) to meet international regulatory standards. Sernova’s research has demonstrated that when the Cell Pouch is inserted under the skin, it forms an ideal environment, rich in microvessels and tissue matrix for the placement and function of therapeutic cells. The Cell Pouch is currently being evaluated in clinical trials at the University of Alberta with Dr. James Shapiro as principal investigator in patients with type 1 diabetes receiving an islet transplant.

It has been shown in multiple preclinical studies to provide a safe environment for transplantation, as well as for the long-term survival and efficacy of therapeutic cells. Sernova's goals for the diabetes indication include making the Cell Pouch available to a wider group of patients than currently possible with intraportal delivery of islets. Sernova also plans to make the Cell Pouch available as a natural, improved site for non-primary-derived, insulin-secreting cells. This may enable long-term treatment in large numbers of patients with insulin-dependent diabetes without limitation to availability of donor-derived cells.

About Sernova Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including haemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch, an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required.

About Clinical Islet Transplantation Program Please view www.islet@ca for more information on the Clinical Islet Transplantation Program at the University of Alberta. For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - February 11, 2015 11 February, 2015

Sernova is Awarded Patents in Multiple Countries for Cell Pouch™ and Therapeutic Cell Transplantation Technologies

Source: Sernova Corp

February 12, 2015, 6:00 a.m. EDT

LONDON, ONTARIO (Marketwire – February 12, 2015) - Sernova Corp. (TSX-V: SVA), today announced that the Patent Offices in China, Israel, Singapore and New Zealand have issued Notices of Allowance and issued patents to Sernova for its patent application entitled "Methods and Devices for Cellular Transplantation.”

These patents help protect Sernova’s entire Cell Pouch(TM) system, including the Cell Pouch(TM) itself, as well as the Cell Pouch(TM) combined with therapeutic cells and surgical tools for cell transplantation. These issued patents, in addition to patent rights already granted or actively being pursued in other countries, will provide Sernova with patent protection through 2030.

“Patent applications on Sernova’s technologies are being pursued in multiple countries around the world and we are confident that additional patents will be granted on an international basis,” stated Dr. Philip Toleikis, Sernova’s President and CEO.

"Potential strategic partners, including major pharmaceutical companies place significant value in issued patents,” stated Dr. Philip Toleikis, Sernova’s President and CEO. He continued, “Since 2009, we have been relentless at carrying out our strategy to secure exclusive patent rights on our core technologies, to develop an international footprint for our products.”

About Sernova

Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova’s proprietary local immune protection technology.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Press Release Communiqué de presse - April 22, 2015 22 April, 2015

Sernova Receives Issued Patent in the United States for its Cell Pouch™ and Therapeutic Cell Transplantation Technologies

Sernova Receives Issued Patent in the United States for its Cell Pouch(TM) and Therapeutic Cell Transplantation Technologies

Sernova’s cell transplantation and local immune protection patent families are secured and protected to maximize stakeholder value

Source: Sernova Corp

April 23, 2015, 6:00 a.m. EDT

LONDON, ONTARIO (Marketwire – April 23, 2015) - Sernova Corp. (TSX-V: SVA), is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has issued Sernova a patent that helps protect Sernova’s entire Cell Pouch System (TM).

This patent entitled "Methods and Devices for Cellular Transplantation” includes claims covering implantable polymer devices such as the Cell Pouch(TM) itself, as well as methods using the same combined with therapeutic cells such as self‐cells, donor cells, stem cells and genetically modified cells as well as surgical tools for cell transplantation. This new patent provides Sernova with patent protection through 2030. Sernova currently has over 55 issued patents and patent pending applications worldwide covering its therapeutic cell transplantation and local immune protection technologies.

The USPTO grants a patent after a vigorous search of the existing technology and a determination that a claimed invention is novel and nonobvious over that technology. Gaining such patent protection is commercially important because the United States represents one of the world’s largest markets for Sernova’s various therapeutic products in development.

“Since 2009, we have pursued patent rights around the world for our cell transplantation and local immune protection technologies and we will continue our rigorous strategy to secure and protect our proprietary technologies,” stated Dr. Philip Toleikis, Sernova’s President and CEO.

Within its patented technological armamentarium, Sernova uses biocompatible polymers to develop unique, highly vascularized subcutaneous tissue chambers for the placement, survival and long term function of therapeutic cells. Over the past six years, Sernova has demonstrated an excellent safety profile and efficacy benefit for its technologies in small and large animal models of disease and, more importantly, in humans with severe diabetes where transplanted therapeutic cells become highly vascularized and able to produce their therapeutic product.

About Sernova

Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova’s proprietary local immune protection technology.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Press Release Communiqué de presse - September 09, 2015 9 September, 2015

Sernova Secures Commercial Rights to Proprietary Stem Cell Derived Technologies

– UHN (University Health Network) agreement transitions Sernova to an integrated therapeutic cell regenerative medicine Company –

Source: Sernova Corp

September 10, 2015, 6:00 a.m. EDT

LONDON, ONTARIO – (Marketwire – September 10, 2015) – Sernova Corp. (TSX-V: SVA) (FSE: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases, announced today it has signed a license agreement with the University Health Network (UHN) of Toronto, Canada to gain exclusive worldwide rights to certain patent-pending technologies developed by distinguished UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller. These technologies relate to the development of stem cells into glucose-responsive therapeutic cells for the treatment of patients with insulin-dependent diabetes.

”This agreement provides us with a proprietary source of stem cell derived glucose responsive therapeutic cells. When placed within Sernova’s prevascularized Cell Pouch(TM), and protected locally from immune system attack, we believe that Sernova has the potential to provide a significant break-through in the quality of treatment for the millions of people suffering from insulin-dependent diabetes, said Dr. Philip Toleikis, Sernova’s President and CEO”. “Such individuals could essentially be liberated from their current onerous daily regime of multiple blood glucose testing and insulin administration delivered through injections or electronic means which is expected to materially improve their quality of life, prevent or reduce abnormal glucose complications, and reduce short term and longer term health care costs.”

The current standard of care for islet transplantation is limited to diabetic patients with severe hypoglycemia unawareness due to both a lack of cadaveric donor islets and a requirement for life-long use of toxic anti-rejection drugs.

“We believe that a virtually unlimited supply of glucose responsive therapeutic cells could be generated from ethically derived stem cells which, if shown to have positive safety and efficacy in clinical trials, could be used to treat millions of patients,” commented Delfina Siroen, Sernova’s head of Research and Development. “The addition of the UHN stem cell technologies moves Sernova one step further toward being able to provide a full solution (device, unlimited cell supply and local immune protection) for cell therapy applications.”

About Diabetes The worldwide incidence of diabetes is approximately 370 million. Sernova’s potential addressable market which includes Type-1 patients and those Type-2 patients requiring insulin is over 30 million people. Although there is currently no cure for diabetes, blood glucose levels are being controlled with frequent blood glucose testing combined with regular injections of insulin via syringe or insulin pump; however, blood glucose control using this treatment approach can be poor, leading to side effects such as heart, kidney and eye diseases as well as ischemia-induced amputations. According to the Juvenile Diabetes Research Foundation, annual health care costs for the treatment of diabetes and its debilitating side effects are estimated to be over US $245 billion per year in North America (http://jdrf.org/).

About Sernova Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch and our expectations of the potential benefits of the license agreement, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Press Release Communiqué de presse - December 20, 2015 20 December, 2015

Sernova Awarded Europe’s Prestigious Horizon 2020 Grant to Fund Development of Cell-based Hemophilia Therapeutic Product into the Clinic

Distinguished European consortium awarded approximately $8.5 Million CAD by the European Commission via its Horizon 2020 Program to partner advanced cell based Factor VIII therapy in collaboration with Sernova and its Cell Pouch(TM) device technologies

Source: Sernova Corp

December 21, 2015, 6:00 a.m. EDT

LONDON, ONTARIO – (Marketwire – December 21, 2015) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, announced today that the European Commission’s Horizon 2020 program has awarded a Euro 5.6M ($8.5M CAD) grant to a consortium consisting of Sernova Corp and five European academic and private partners to advance development of a GMP clinical grade Factor VIII releasing therapeutic cell product in combination with Sernova’s Cell Pouch(TM) for the treatment of severe hemophilia A, a serious genetic bleeding disorder caused by missing or defective factor VIII in the blood stream.

The current market for factor VIII is US$5.0B/year, with a cost of up to US$260,000 per patient each year. Current standard of care involves regular infusions of factor VIII, which achieves normal factor VIII blood levels for only a few hours at a time. The product being developed by the HemAcure consortium will seek to provide constant delivery of Factor VIII to normalize blood levels in an effort to significantly improve the quality of life of patients suffering from hemophilia A.

The product being developed by the HemAcure consortium is expected to be highly disruptive to the current standard of care treatments for hemophilia A. The therapeutic goal of the product is to use the patient’s own cells corrected for the factor VIII gene. These cells placed in the implanted Cell Pouch will release factor VIII on a continual basis at a rate that would be expected to significantly reduce disease-associated hemorrhaging and joint damage. The constant delivery of factor VIII is also expected to reduce or eliminate the need for multiple weekly infusions which is the current standard of care using plasma-derived or recombinant, genetically engineered factor VIII for the prophylactic treatment of hemophilia A.

“The therapeutic potential to have a constant release of factor VIII from a hemophilia A patient’s own genetically corrected cells placed within the implanted Cell Pouch would be a very significant advance in the treatment of hemophilia A,” remarked Dr. David Lillicrap, MD, FRCPC Professor Department of Pathology and Molecular Medicine Queens University, Canada Research Chair in Molecular Hemostasis and member of the HemAcure Scientific Advisory Board. “Sernova’s Cell Pouch with its vascularized tissue lined chambers for therapeutic cells, which has already been proven for islet safety and survival in human clinical assessment of diabetes, is an ideal, fully scalable first-in-class medical device suitable for the potential treatment of hemophilia,” added Dr. Lillicrap.

“It has been exciting working together with the highly skilled team of experts in the HemAcure consortium in hemophilia and cell therapy. The scientific strength of this consortium was evident from the inception of the idea through the development and awarding of the grant to the stimulating kick off meeting,” said Delfina Siroen, Sr. Director of Sernova’s Research and Development team. “In a very short time, Sernova’s hemophilia program has achieved great strides and the addition of this European grant and team will ensure the best possible outcome for this program to the clinic,” continued Ms. Siroen.

The preliminary preclinical proof of concept data used as a basis to support the foundation of the grant was generated in a collaborative agreement between Medicyte GmbH under the FP7 ReLiver project, grant agreement 304961 and Sernova Corp where cryopreserved cells with the ex vivo inserted corrected gene for factor VIII were successfully shipped and assessed in Sernova’s Cell Pouch at its headquarters in Canada. Regarding Sernova’s participation in the consortium, the review of the HemAcure grant proposal stated the following, “Participation of the third country partner (Sernova Corp) is essential for carrying out the (program). This is justified by the fact that the partner in question is the one who possesses the technology that will be the basis of the whole proposal, and which will perform all the in vivo studies. Sernova uses a scalable, contract manufactured, proprietary patented worldwide implantable medical device (Cell Pouch) transplanted with therapeutic cells. (It) has been in development for more than six years and has shown success in multiple small and large animal preclinical models and is now in a clinical trial for another therapeutic indication. This Cell Pouch device is the only such device that when implanted under the skin is proven to become incorporated with blood vessel enriched tissue-forming chambers for the placement of therapeutic cells. This implies that the Canadian partner (Sernova) is an essential partner for the success of this project.”

About Hemophilia A

People with Hemophilia have prolonged abnormal bleeding as a result of trauma. Hemophilia A, also called factor VIII (FVIII) deficiency is the most common form of Hemophilia and is a genetic disorder caused by missing or defective factor VIII, a blood clotting protein. Severe hemophilia occurs in about 60% of cases where the deficiency of Factor VIII is less than 1% of normal blood concentration. While it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous change in the gene. According to the US Centers for Disease Control and Prevention hemophilia occurs in about 1 in 5,000 births. If the prolonged bleeding occurs in the brain of a person with hemophilia, it can be fatal. Prolonged bleeding in joints can cause inflammatory responses and permanent joint damage. Approximately 20,000 people in the United States and 10,000 in Europe have the moderate or severe form of hemophilia A, as well as approximately 2,500 in Canada. All races and ethnic groups are equally affected by hemophilia A. Though there is no cure for the disease, it can be controlled with regular infusions of recombinant clotting Factor VIII. Annual costs for the treatment of the disease for each patient may range from $60,000 to $260,000 US for a total cost of between $2-5B per year in North America and Europe.

About Horizon 2020 Programme

Horizon 2020 is the biggest EU Research and Innovation program ever with nearly Euro 80 billion of funding available over seven years (2014 to 2020). It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. The project is funded as part of societal challenges “personalizing health and care” in a specific call about innovative treatments and technologies. New therapies, such as gene or cell therapies, often require technological innovation in the form of development of specific component tools and techniques such as isolation and multiplication of a cell or development of a scaffold, delivery of the therapy to the patient and for following-up the effect of the therapy in the patient. In particular, achieving therapeutic scale production and GMP standards at reasonable cost is often underestimated. The European Union aims to improve the development of advanced methods and devices for targeted and controlled delivery, and to bring these innovative treatments to the patient.

About HemAcure

HemAcure is the name of the consortium developing a product for hemophilia A. This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 667421. The consortium members include the University Hospital Wurzburg (Coordinating Institute), Integrierte Management Systeme IMS e.K., Universita del Piemonte Orientale “Amedeo Avogadro,” Loughborough University, GABO:mi Gesellschaft für Ablauforganisation: milliarium mbH & Co. and Sernova Corp. The main objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell based therapy within Sernova’s prevascularized Cell Pouch to treat this bleeding disorder that should ultimately lead to improved quality of life of the patients.

About Sernova

Sernova Corp is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch and our expectations of the potential benefits of the consortium and the Horizon 2020 hemophilia project, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Press Release Communiqué de presse - January 25, 2016 25 January, 2016

Sernova Announces Agreement with CCRM to Produce Specialized Cells for the Treatment of Diabetes

CCRM to establish, optimize and validate methods for producing Sernova’s transformative cell-based therapies for Type-1 diabetes

Source: Sernova Corp

January 26, 6:00 a.m. EDT

LONDON, ONTARIO – (Marketwire – January 26, 2016) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, announced today it has entered into a service agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to establish, optimize and validate Sernova’s licensed technology for creating stem cell derived therapeutic cells that produce insulin and are glucose responsive.

“Sernova’s Cell Pouch System(TM) is a novel, preclinically validated and clinically tested platform for multiple types of therapeutic cells, including human islets,” said Dr. Philip Toleikis, President and CEO Sernova Corp. “Sernova’s CCRM partnership with CCRM’s expertise in developing production processes for cellular therapies is an important step in Sernova’s plan to commercialize an unlimited supply of glucose responsive, insulin producing cells for the Cell Pouch System. Sernova continues to seek out and evaluate optimal unlimited cell sources both internally developed and through corporate partnerships involving stem cell derived, and xenogeneic cell sources. Our manufacturing partnership with CCRM will provide the ability for the scale up production required to ensure successful commercialization of Sernova’s cellular therapies for diabetes,” added Dr. Philip Toleikis.

CCRM is a unique not-for-profit group that is solely focused on developing and commercializing cell therapy and regenerative medicine technologies. Sernova is a member of CCRM’s industry consortium, a group of nearly 50 companies formed to address bottlenecks in cell therapy and regenerative medicine product pipelines by enabling industry to engage with CCRM’s broad network of researchers and institutions. Industry consortium members represent key sectors in regenerative medicine – therapeutics, devices, reagents and cells as tools – and tremendous industry experience.

"As a member of CCRM’s industry consortium, Sernova is a valued partner in our quest to develop global breakthroughs in regenerative medicine,” remarked Michael May, President and CEO of CCRM. “Commercializing a regenerative medicine therapy for diabetes – the goal for Sernova and CCRM – has the potential to disrupt and transform current standard of treatment. We are excited about the timing of this partnership,” added Dr. May, “as it is our expectation that projects like this become candidates for the new advanced manufacturing initiative that we announced during a visit by Prime Minister Trudeau in mid-January.”

About Sernova

Sernova Corp. is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System, an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch System and our cell technologies, and manufacturing capabilities of CCRM are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Press Release Communiqué de presse - February 04, 2016 4 February, 2016

Sernova Honoured as Member of the “2016 TSX Venture 50” and Ranked #4 in Life Sciences and Clean Technologies

Sernova resides in the top 3% of TSX Venture Exchange Companies in market performance

Source: Sernova Corp

February 5, 6:00 a.m. EDT

LONDON, ONTARIO – (Marketwire – February 5, 2016) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing medical technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, announced today it has received the ranking of fourth in the category of Life Sciences and Clean Technologies and has been selected as member of the “2016 TSX Venture 50” Companies. This is a prestigious group of top market performers from among the 1,791 companies listed on the Toronto Venture Exchange as of December 31, 2015. "We are honoured to be distinguished by the TSX from amongst all TSX Venture Companies and are appreciative of our investors who have rewarded our progress as acknowledged through the TSX Venture Exchange,” remarked Dr. Philip Toleikis, President and CEO. “We congratulate our peer companies in this category who have shown superior results in key metrics of market performance such as market capitalization growth, share price appreciation and trading volume – with Sernova providing a return of 118% in market cap appreciation in 2015. The shares of these companies also enjoyed a liquid market, with a total of 3.0 billion shares traded over the course of 2015,” added Dr. Toleikis.

“Sernova’s ongoing development of its platform technologies for cell therapy, the advancement of it programs in diabetes and hemophilia, and its focus on forging mutually beneficial pharmaceutical collaborations will, we believe, make 2016 another rewarding year for our shareholders and investors,” stated Frank Holler, Sernova Chairman. “This TSX Venture recognition adds to our growing profile in the public markets and we are most appreciative of receiving this distinction," added Mr. Holler.

About Sernova

Sernova Corp. is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System, an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch System and our cell technologies, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Press Release Communiqué de presse - July 11, 2016 11 July, 2016

Sernova and JDRF Announce Funding of Joint Research Collaboration to Advance Human Clinical Trials for the Treatment of Hypoglycemic Unawareness Patients with Severe Type 1 Diabetes

$2.45 million USD awarded to advance Sernova’s Cell Pouch System(TM) (CPS) technologies in a US FDA Clinical Trial with Initiation Scheduled for the Second Half of 2016

Source: Sernova Corp July 12, 2016, 6:00 a.m. EDT

LONDON, ONTARIO – (Marketwire – July 12, 2016) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, is pleased to announce today it has entered into a research funding agreement with JDRF, the leading global organization funding and advocating for type 1 diabetes (T1D) research. The purpose of the funding is to advance human clinical trials of Sernova’s CPS technologies for treatment of hypoglycemia unawareness patients with severe type 1 diabetes. T1D is a life-threatening disease in which the body's immune system mistakenly attacks and kills the pancreatic cells that produce insulin—a hormone that is essential for life because of its role to help the body use glucose.

JDRF will provide Sernova up to $2.45 million USD to support a clinical trial at a major transplantation center in the United States. The goal of the study is to provide patients with hypoglycemia unawareness a novel cell therapy treatment utilizing Sernova’s proprietary, highly vascularized, cell macroencapsulated implantable and scalable device to reduce or eliminate the need for injections of exogenous insulin. “JDRF has previously provided funding to advance the development of Sernova’s technologies through a preclinical collaboration with Massachusetts General Hospital, and we are proud to continue our support as Sernova’s technologies progress into new safety and efficacy clinical trials,” said Derek Rapp, JDRF President and CEO. “JDRF is excited about this collaboration, which advances research in encapsulated cell therapies, and will continue to drive progress toward our mission to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications.” “Sernova and JDRF are tightly aligned in our vision to see cell-based therapies developed to reduce disease burden and significantly increase the quality of life for people living with T1D,” remarked Dr. Philip Toleikis, Sernova’s President and CEO. “We see our work with JDRF on this important clinical trial as an exciting opportunity to more rapidly advance Sernova’s therapies to treat people with diabetes and address many of the shortcomings and challenges of current insulin therapy.” “Sernova’s progression to human clinical trials is an incredible accomplishment in the global diabetes research agenda,” said Dave Prowten, President and CEO of JDRF Canada. “I am particularly proud of this trial being a part of the JDRF portfolio because it supports advancements of the best and brightest research minds in Canada at Sernova. Also, this is a shining example of the international collaboration fostered by projects funded by JDRF. Working together with our global partners, we can accelerate this type of transformative research and ensure it becomes available for the T1D community.”

To date, there is no cure for T1D, and people living with the disease are dependent on insulin therapy to help keep their blood-sugar levels from spiking too high, which can lead to long-term complications such as kidney and heart diseases or an acute, potentially deadly health crisis. Present-day insulin therapy is, however, an imperfect treatment method that requires people with T1D to carefully monitor their blood sugar throughout the day and take multiple, calculated doses of insulin based on food intake, exercise, stress, illness and other factors. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with T1D achieve their long-term blood glucose targets, placing them at risk for T1D-related health complications.

About Sernova Sernova Corp is a clinical stage regenerative medicine Company developing highly disruptive medical technologies to improve the treatment and quality of life of people with chronic debilitating metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch System, an implantable medical device which forms highly vascularized chambers, ideal for therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required to treat disease. For more information, please visit Sernova.com or follow us on Twitter: @SernovaCorp

About JDRF JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested nearly $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - December 10, 2017 10 December, 2017

Sernova Receives US FDA IND Allowance to Initiate a US Clinical Trial of its Cell Pouch for the Treatment of Type 1 Diabetes

Source: Sernova Corp December 11, 2017, 6:00 a.m. EDT

LONDON, ONTARIO – (Globe Newswire – Monday December 11, 2017) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing regenerative medicine technologies for the long-term treatment of diseases including diabetes and hemophilia, is pleased to announce it has received US Food and Drug Administration (FDA) notice of allowance for its IND for a new human clinical trial with the Cell Pouch System (TM) (CPS) in the United States. The Company will host a conference call for shareholders with Dr. Philip Toleikis, President and CEO on Monday, December 11th at 10:00am Eastern Standard Time to discuss the trial.

Sernova plans to initiate the new clinical trial under this US IND to investigate the Cell Pouch for treatment of type 1 diabetes (T1D) in individuals with hypoglycemia unawareness. The trial is a Phase I/II prospective single arm study of islets transplanted into the subcutaneously implanted Cell Pouch. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation into the Cell Pouch and the secondary objective is to assess efficacy through a series of defined measures.

JDRF has previously committed to provide Sernova up to $2.45 million USD to support the clinical trial.

“Hypoglycemia unawareness is a serious consequence of type 1 diabetes,” said Derek Rapp, President & CEO, JDRF International. “We are excited to see progress in this and other potentially life-saving JDRF-funded research, which could help prevent people with hypoglycemia unawareness from experiencing dangerous lows, as we strive to achieve our vision of a world without T1D.”

“We are extremely enthusiastic about the promise of Sernova’s regenerative medicine platform to provide a new therapeutic option for diabetes patients with hypoglycemia unawareness. We believe Sernova’s multiple advancing cell based therapies have the potential to deliver significant improvement in the quality of life of patients suffering from diabetes and other debilitating diseases,” said Dr. Philip Toleikis, Sernova’s president & CEO.

About the Trial

The study is a Phase I/II single site, single arm, Company sponsored trial. Following approval by the Institutional Review Board, patients with hypoglycemia unawareness will be enrolled into the study under informed consent. Patients will then be implanted with the Cell Pouch including sentinel devices. Following vascularized tissue development, a dose of purified islets under strict release criteria will be transplanted into the Cell Pouch and patients followed for safety and efficacy measures for approximately six months. At this point a decision will be made whether to transplant a second islet dose with subsequent safety and efficacy follow up. Patients will then be further followed for one year.

“Sernova’s FDA clearance to commence human clinical trials in the United States is an exciting step forward in diabetes research, initially focused to reduce the risk of hypoglycemia unawareness, a complication in which a patient is unaware of a deep drop in blood sugar that can have life threatening consequences,” said Dave Prowten, President and CEO of JDRF Canada. “This is also an example of the international collaboration fostered by JDRF-funded projects to accelerate transformative research to benefit the T1D community,” added Mr. Prowten.

About Sernova’s Cell Pouch

The Cell Pouch is a novel, proprietary, scalable, implantable macroencapsulation device for the long-term survival and function of therapeutic cells (donor, stem cell derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device is designed upon implantation to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin producing cells in humans.

About Diabetes

T1D is a life-threatening disease in which the body's immune system mistakenly attacks and kills the pancreatic cells that produce insulin—a hormone that is essential for life because of its role to help the body use glucose. The existing standard of care for patients with TID is suboptimal. To date, there is no cure for T1D, and people living with the disease are dependent on exogenous insulin therapy to help keep their blood-sugar levels from spiking too high, which can lead to long-term complications such as kidney and heart diseases or an acute, potentially deadly health crisis. Present-day insulin therapy is, however, an imperfect treatment method that requires people with T1D to carefully monitor their blood sugar throughout the day and take multiple, calculated doses of insulin based on food intake, exercise, stress, illness and other factors. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with T1D achieve their long-term blood glucose targets, placing them at risk for T1D-related health complications.

Conference Call Details

To participate in this live conference call, please dial + 1-877-858-5743 prior to the scheduled conference call time. International callers should dial +1-858-609-8959. The conference participant pass code is 355 040. Following the conference call a recording will be available at www.sernova.com

About Sernova Corp

Sernova Corp is developing disruptive regenerative medical technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested nearly $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778\ www.raymatthews.ca ray@raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - February 21, 2018 21 February, 2018

Sernova’s Cell Pouch Regenerative Medicine Clinical Trial for Patients with Type 1 Diabetes Supported with Continuous Glucose Monitoring Systems

Continuous Glucose Monitoring System (CGM) to provide sensitive tracking of key efficacy measures in patients at important time points throughout the study

Source: Sernova Corp February 22, 2018, 6:00 a.m. EDT

LONDON, ONTARIO – (Globe Newswire – February 22, 2018) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing regenerative medicine technologies for the treatment of chronic diseases including diabetes and hemophilia, is pleased to announce continuous glucose monitoring systems (CGM (Medtronic Minimed, Northridge, CA)) will be provided to patients in Sernova’s US regenerative medicine clinical trial of its Cell Pouch(TM). CGM will be used to track the function of the transplanted cells in the measurement of key efficacy measures at multiple time points following transplantation of the therapeutic cells into the Cell Pouch.

Glucose variability and hypoglycemia duration can be determined using CGM. CGM involves the subcutaneous placement of a glucose sensor connected to a pager-sized monitoring device that stores glucose data over a 6-day period. Data from each period will be analyzed for mean glucose concentration, mean glucose variability, number and duration of hyper- and hypo- glycemic episodes, and total duration of hypoglycemia.

“We believe continuous glucose monitoring of patients may be an important and sensitive method to closely track the function of the transplanted therapeutic cells within the Cell Pouch,” said Dr. Philip Toleikis, Sernova’s President and CEO. “We are pleased with our collaborators in this study who have shown the foresight to support Type 1 diabetes patients seeking treatment via next-generation regenerative medicine technologies.”

Sernova has recently received US Food and Drug Administration (FDA) notice of allowance for its IND for a new human clinical trial with the Cell Pouch System (CPS) in the United States. Sernova is taking final steps to begin enrollment of patients in the new clinical trial under this US IND to investigate the Cell Pouch for treatment of type 1 diabetes (T1D) in individuals with hypoglycemia unawareness. The trial is a Phase I/II prospective single arm study of islets transplanted into the subcutaneously implanted Cell Pouch. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation into the Cell Pouch and the secondary objective is to assess efficacy through a series of defined measures.

About the Trial The study is a Phase I/II single site, single arm, Company sponsored trial. Following approval by the Institutional Review Board, patients with hypoglycemia unawareness will be enrolled into the study under informed consent. Patients will then be implanted with the Cell Pouch including sentinel devices. Following vascularized tissue development, a dose of purified islets under strict release criteria will be transplanted into the Cell Pouch and patients followed for safety and efficacy measures for approximately six months. At this point a decision will be made whether to transplant a second islet dose with subsequent safety and efficacy follow up. Patients will then be further followed for one year. CGM is planned to provide a sensitive and accurate tracking method to follow important efficacy measures at various time points throughout the study.

About Sernova’s Cell Pouch The Cell Pouch is a novel, proprietary, scalable, implantable macroencapsulation device for the long-term survival and function of therapeutic cells (donor, stem cell derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device is designed upon implantation to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long term safety and efficacy in small and large animal models with diabetes and has been proven to provide a biologically compatible environment for insulin producing cells in humans.

About Diabetes T1D is a life-threatening disease in which the body's immune system mistakenly attacks and kills the pancreatic cells that produce insulin—a hormone that is essential for life because of its role to help the body use glucose. The existing standard of care for patients with TID is suboptimal. To date, there is no cure for T1D, and people living with the disease are dependent on exogenous insulin therapy to help keep their blood-sugar levels from spiking too high, which can lead to long-term complications such as kidney and heart diseases or an acute, potentially deadly health crisis. Present-day insulin therapy is, however, an imperfect treatment method that requires people with T1D to carefully monitor their blood sugar throughout the day and take multiple, calculated doses of insulin based on food intake, exercise, stress, illness and other factors. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with T1D achieve their long-term blood glucose targets, placing them at risk for T1D-related health complications.

About Sernova Corp Sernova Corp is developing disruptive regenerative medical technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778\ www.raymatthews.ca ray@raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - May 07, 2018 7 May, 2018

Sernova Announces U.S. Phase I/II Cell Pouch Clinical Trial with Prominent Diabetes Clinical Investigator

Leading Surgeon and Researcher in Islet Transplantation at the University of Chicago to act as Clinical Trial Principal Investigator. Study to focus on severely diabetic patients with hypoglycemia unawareness

Source: Sernova Corp

May 8, 2018, 6:00 a.m. EDT

LONDON, ONTARIO – (Globe Newswire May 8, 2018) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), announces Dr. Piotr Witkowski, M.D., Ph.D., a leading expert in type 1 diabetes (T1D) and islet transplantation, as the Clinical Trial Principal Investigator for Sernova’s new clinical study. Dr Witkowski, at the University of Chicago site, will work closely with Sernova’s team to conduct the clinical and regulatory aspects of the Cell Pouch trial.

Dr. Witkowski is a widely published diabetes researcher and respected surgeon with a longstanding record of success in both basic science and clinical research pertaining to islet cell and abdominal organ transplantation. Among other accomplishments, he was instrumental in developing an optimized islet isolation technique that greatly improved success in clinical transplants. Under Dr. Witkowski's leadership, multidisciplinary research teams at the University of Chicago are currently conducting several studies designed to improve the quality and outcomes of islet cell transplantation in patients with T1D.

“Sernova’s achievement to commence US human clinical trials is a key step to improving the therapeutic treatment for people living with diabetes. This Cell Pouch safety and efficacy trial aims to reduce the risk of hypoglycemia unawareness, a complication in which a patient is unable to recognize and control impending hypoglycemia resulting in a drop in blood sugar that can have life threatening consequences,” said Dr. Witkowski. “Our experienced diabetes treatment team at the University of Chicago sees the potential of this transformative therapy to benefit and substantially improve the care of T1D.”

“Improving the quality of life and outcomes of people with diabetes are Sernova’s main priorities, and we are grateful to have the opportunity to work with Dr. Witkowski and his expert team at the University of Chicago, a team known for outstanding diabetes research and patient care,” stated Dr. Philip Toleikis, Sernova’s President & CEO.

The study is a Phase I/II, non-randomized, unblinded, single-arm, company sponsored trial. Under the clinical leadership of Dr. Witkowski, University of Chicago Medicine, patients with hypoglycemia unawareness will be enrolled in the study under informed consent. Patients then will be implanted with the Cell Pouch including sentinel devices. Following vascularized tissue development in the Cell Pouch, an initial dose of purified islets under strict release criteria will be transplanted into the Cell Pouch and patients followed for safety and efficacy measures for approximately six months. At this point a decision will be made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will then be further followed for one year, with interim patient results released at periodic intervals consistent with an open label study.

About Dr. Witkowski Piotr Witkowski M.D. Ph.D. is an Associate Professor of Surgery and a transplant surgeon at the University of Chicago Medicine. He has been involved in islet transplantation research for the past 17 years, initially at Columbia University in New York City and then as a Director of the Pancreatic Islet Transplantation Program at the University of Chicago Medicine. For the last nine years, Dr. Witkowski has been conducting multiple clinical studies in intraportal islet allotransplantation in patients with brittle type diabetes as well as islet autotransplantation in patients with chronic pancreatitis. Recently, he accomplished a phase 3 clinical trial and is currently preparing application to the FDA for islet graft as a biological product, which is pivotal to enable islet transplantation to become available to patients as a standard of care procedure. Being aware of shortcomings of intrahepatic islet transplantation, Dr Witkowski has been working on optimization of the subcutaneous location for improved islet engraftment. He has proven the concept that this pre-vascularized site enhances islet survival in a preclinical diabetes model.

About Sernova Corp Sernova Corp is developing disruptive regenerative medical technologies using a medical device (Cell Pouch) and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939; philip.toleikis@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778; www.raymatthews.ca ray@raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - May 13, 2018 13 May, 2018

Sernova Announces University of Chicago Institutional Review Board (IRB) Approval of the FDA-cleared Therapeutic Cell Pouch Clinical Study

IRB Approval Signals ‘Green Light‘ for Sernova’s Clinical Protocol to Proceed

Source: Sernova Corp

May 14, 2018 6:00 a.m. EDT

LONDON, ONTARIO – (Globe Newswire – Monday May 14, 2018 ) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), announces today it has received University of Chicago Institutional Review Board (IRB) approval to begin a new clinical protocol for the FDA-cleared human clinical trial to investigate the Cell Pouch™ for treatment of type 1 diabetes (T1D) in individuals with hypoglycemia unawareness.

The University of Chicago Institutional Review Board (IRB) is a committee established to review and approve research involving human subjects. The purpose of the IRB is to ensure that all human subject research is conducted in accordance with all federal, institutional, and ethical guidelines. The primary goal of an IRB is to safeguard the rights, safety and welfare of participants in research studies.

"The approval of our clinical protocol by the University of Chicago IRB represents a significant milestone enabling the company to expand the clinical testing of our Cell Pouch System to the US. Patient selection and enrollment can now proceed," said Dr. Philip Toleikis, Sernova President and CEO.

The approved protocol is a Phase I/II non-randomized, unblinded, single arm, company- sponsored trial, where diabetic subjects with hypoglycemia unawareness will be enrolled into the study under informed consent. Subjects will then be implanted with Cell Pouches. Following development of vascularized tissue chambers within the Cell Pouch, subjects will then be stabilized on immunosuppression and a dose of purified islets under strict release criteria will be transplanted into the Cell Pouch.

A sentinel pouch, also transplanted with islets, will be removed for an early assessment of the islet transplant. Subjects will be followed for safety and efficacy measures for approximately six months. At this point, a decision will be made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will then be further followed for one year. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation into the Cell Pouch™. The secondary objective is to assess efficacy through a series of defined measures.

About Sernova’s Cell Pouch™ Technologies The Cell Pouch™ is a novel, proprietary, scalable, implantable macroencapsulation device designed to prevent device fibrosis for the long-term survival and function of therapeutic cells (donor, stem cell-derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device is designed upon implantation to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans

About Diabetes T1D is a life-threatening disease, affecting more than 3.3 million individuals in Canada and US, in which the body's immune system mistakenly attacks and kills the pancreatic cells that produce insulin a hormone that is essential for life because of its role to help the body use glucose. The existing standard of care for patients with TID is suboptimal. To date, there is no cure for T1D, and people living with the disease are dependent on exogenous insulin therapy to help keep their blood-sugar levels from spiking too high, which can lead to long-term complications such as kidney and heart diseases or an acute, potentially deadly health crisis. Present-day insulin therapy is, however, an imperfect treatment method that requires people with T1D to carefully monitor their blood sugar throughout the day and take multiple, calculated doses of insulin based on food intake, exercise, stress, illness and other factors. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with T1D achieve their long-term blood glucose targets, placing them at risk for T1D-related health complications.

About Sernova Corp Sernova Corp is developing disruptive regenerative medical technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases. For more information, please visit www.sernova.com

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939; philip.toleikis@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778; www.raymatthews.ca ray@raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - July 04, 2018 4 July, 2018

Sernova Initiates Patient Screening and Recruitment for its US Clinical Trial for Diabetes

Source: Sernova Corp

July 5, 2018, 6:00 a.m. EDT

LONDON, ONTARIO –July 5, 2018 – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) announces that patient screening and recruitment has begun in its regenerative medicine US clinical trial for diabetic patients with hypoglycemia unawareness.

Sernova’s initial clinical evaluation of the prevascularized Cell Pouch (TM) demonstrated biocompatibility and safety of the Cell Pouch as well as viability and vascularization of its transplanted insulin-producing islets, a first in world achievement in a prevascularized implantable medical device.

“This first-in-human work helped frame the design of Sernova’s new Phase I/II clinical protocol. Our clinical team at the University of Chicago is excited to initiate this trial of Sernova’s transformative technology,” said principal investigator, Dr. Piotr Witkowski, M.D., Ph.D.

“To support the clinical study’s timely execution under the highest quality standards, Sernova and CTI (Clinical Trial and Consulting), a well-respected clinical research organization with deep experience in the regenerative medicine field, are working closely with Dr. Witkowski’s team,” said Dr. Philip Toleikis, Sernova’s President and CEO.

The study is a Phase I/II, non-randomized, open label, single-arm, company-sponsored trial. Under the clinical leadership of Dr. Witkowski, University of Chicago Medicine, subjects with hypoglycemia unawareness enrolled in the study under informed consent will be implanted with the Cell Pouch. Following vascularized tissue development in the Cell Pouch, an initial dose of purified islets under strict release criteria will be transplanted into the Cell Pouch.

A sentinel pouch, also transplanted with islets, will be removed for an early assessment of the islet transplant. Subjects will be followed for safety and efficacy measures for approximately six months. At this point, a decision will be made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Subjects will then be further followed for one year, with interim participants results released at periodic intervals consistent with an open-label study.

About Sernova’s Cell Pouch Technologies

The Cell Pouch is a novel, proprietary, scalable, implantable prevascularized macroencapsulation device for the long-term survival and function of therapeutic cells (donor, stem cell derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device is designed to eliminate concerns of fibrosis upon implantation by incorporating with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long- term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

About Diabetes

Type1 Diabetes (T1D) is a life-threatening disease in which the body's immune system mistakenly attacks and kills the pancreatic cells that produce insulin—a hormone that is essential for life because of its role to help the body use glucose. The existing standard of care for patients with TID is suboptimal. To date, there is no cure for T1D, and people living with the disease are dependent on exogenous insulin therapy to help keep their blood-sugar levels from spiking too high, which can lead to long-term complications such as kidney and heart diseases or an acute, potentially deadly health crisis. Present-day insulin therapy is, however, an imperfect treatment method that requires people with T1D to carefully monitor their blood sugar throughout the day and take multiple, calculated doses of insulin based on food intake, exercise, stress, illness and other factors. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with T1D achieve their long-term blood glucose targets, placing them at risk for T1D- related health complications.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using an implantable medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 Philip.toleikis@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - November 20, 2018 20 November, 2018

Sernova Highlights Achievements from the HemAcure Consortium in Developing a Novel Cell-Based Therapy for Hemophilia A

Source: Sernova Corp

November 20, 2018, 8:30 a.m. EST

LONDON, ONTARIO –November 20, 2018 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) a clinical-stage regenerative medicine company, highlights the achievements in developing a novel cell-based therapy in combination with Sernova’s Cell Pouch™ for treatment of Hemophilia A.

The therapeutic significance of this work supports the HemAcure Consortium’s concept that Factor VIII genetically corrected human cells from a blood sample of patients with Hemophilia A transplanted into the Cell Pouch can improve blood clotting.

“I am impressed with the achievements of this International Consortium within the limited time allowed. The technical teams worked closely together to complete this work in developing a first-in-world ex vivo gene therapy approach in an implanted vascularized medical device for the treatment of Hemophilia A.” said Dr. David Lillicrap, Professor in the Department of Pathology and Molecular Medicine at Queen’s University, member of the Medical Advisory Board of the World Federation of Hemophilia, and HemAcure Scientific Advisory Board member.

A summary of the Consortium’s achievements are as follows:

• In blood donated from patients with Hemophilia A, endothelial outgrowth cells to be corrected for the Factor VIII gene were isolated and grown successfully in a specialized Good Manufacturing Process (cGMP) compliant medium developed by the Consortium.

• Using a human Factor VIII gene insertion technique, the cells were corrected and confirmed to produce Factor VIII.

• A preliminary experiment showed these cells could release Factor VIII in the blood over time and improve blood clotting in an animal model of Hemophilia A, in preparation for transplant into the Cell Pouch.

• The corrected cells were proven to be successfully replicated through a production scale-up process. Following amplification, these cells maintained their normal healthy behavior in producing Factor VIII. Additional safety metrics were achieved using established tests.

• The cells were then cryopreserved and shipped from the European partners to Sernova in North America where they were shown to remain healthy through quality control testing in preparation for transplantation.

• The Cell Pouch, manufactured under cGMP, and following implantation in the Hemophilia A animal model showed development of vascularized chambers suitable to receive the corrected cells.

• Following transplantation into the Cell Pouch in a Hemophilia A animal model, the patient’s Factor VIII corrected cells survived at three months (the duration of the study).

• Initial results showed Factor VIII released from the cells in the Cell Pouch was detected in blood and notably, showed improved clotting when compared to the Hemophilia A animal control which did not receive human corrected cells.

• The steps of the cell production process were documented towards development of the cGMP manufacturing process for the corrected cells for future clinical use. An Instructions-for-Use document was also developed for implantation of the cGMP Cell Pouch and transplantation of patient corrected Factor VIII producing cells applicable for future human testing in patients with Hemophilia A.

Sernova’s President & CEO, Dr. Philip Toleikis added, “These series of breakthroughs demonstrate success in correcting a Hemophilia A patient’s own cells to produce the missing Factor VIII protein and to improve blood clotting in an animal model of Hemophilia A in preparation for future human clinical trials.”

Technical results will continue to be presented by HemAcure Consortium members at scientific conferences and disseminated in scientific publications. Furthermore, steps are to complete cGMP manufacturing of the cells using the tools and methods developed by the Consortium, optimize dosing of cells in the Cell Pouch to achieve optimal therapeutic blood levels of Factor VIII, and conduct final formal studies in preparation for a first-in- human clinical study.

HemAcure’s webinar in which the consortium expert leaders present an overview of the findings is now available both on Sernova’s website at www.sernova.com and the HemAcure project website at www.hemacure.eu

About HemAcure

The overall objective of the HemAcure project is to develop and refine the tools and technologies for a novel ex vivo prepared cell-based therapy to treat the bleeding disease, Hemophilia A (caused by a genetic deficiency in clotting Factor VIII (FVIII)) that should ultimately lead to improved quality of life of the patients. The European Union's Horizon 2020 research and innovation program has awarded approximately €5.5 million (CDN$8.5) to support the project. International consortium members include the University Hospital Wuerzburg (Coordinating Institute), Germany, IMS - Integrierte Management, Heppenheim, Germany, Università del Piemonte Orientale “Amedeo Avogadro,” Novara, Italy, Loughborough University, Loughborough, United Kingdom, ARTTIC International Management Services, Munich, Germany and Sernova Corp., London, Ontario, Canada. This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No 667421. The Consortium has been working together to provide sets of design and manufacturing protocols, based on current European GMP regulations to prepare an Investigational Medicinal Product Dossier (IMPD) for an Investigational Medicinal Product (IMP), composed of therapeutic cells and an implantable medical device (Sernova’s Cell Pouch). For more information, visit www.hemacure.eu

About Hemophilia A

People with Hemophilia A have prolonged abnormal bleeding as a result of trauma. Hemophilia A is the most common form of Hemophilia and is a genetic disorder caused by missing or defective FVIII, a blood clotting protein. Severe Hemophilia A occurs in about 60% of cases where the deficiency of FVIII is less than 1% of normal blood concentration. While it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous change in the gene. According to the US Centers for Disease Control and Prevention, Hemophilia A occurs in about 1 in 5,000 births. Prolonged bleeding, in areas such as the brain, of a person with Hemophilia A, can be fatal. Prolonged bleeding in joints can cause inflammatory responses and permanent joint damage. Approximately 20,000 people in the United States, 2,500 in Canada and 10,000 in Europe have moderate to severe forms of Hemophilia A. Though there is no cure for the disease, Hemophilia A can be controlled with regular infusions of recombinant clotting FVIII. Annual worldwide costs for the treatment of the disease for each patient may range from $60,000 to $260,000 US for a total cost of approximately $15B per year.

About Horizon 2020 Programme

Horizon 2020 is the biggest EU Research and Innovation program ever with nearly €80 billion of funding available over seven years (2014 to 2020). It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. The project is funded as part of societal challenges “personalizing health and care” in a specific call about innovative treatments and technologies. New therapies, such as gene or cell therapies, often require technological innovation in the form of development of specific component tools and techniques such as isolation and multiplication of a cell or development of a scaffold, delivery of the therapy to the patient and for following-up the effect of the therapy in the patient. In particular, achieving therapeutic scale production and cGMP standards at reasonable cost is often underestimated. The European Union aims to improve the development of advanced methods and devices for targeted and controlled delivery, and to bring these innovative treatments to the patient.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including Hemophilia A, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

Danny Matthews, Solebury Trout Tel: (646) 378-2928 dmatthews@soleburytrout.com www.soleburytrout.com

Dominic Gray, Corporate Communications Tel: (519) 858-5126 Dominic.Gray@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of the Hemophilia A program. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

HemAcure Webinar: https://youtu.be/ihyHefvJ8cQ

Press Release Communiqué de presse - December 20, 2018 20 December, 2018

Sernova Announces Enrollment of First Patient in U.S. Phase I/II Study of Cell Pouch for Treatment in Type 1 Diabetes

Initiating Treatment Phase of the Study at the University of Chicago

December 20, 2018 9:00 a.m. EST

LONDON, ONTARIO – December 20, 2018 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine company announces the enrollment of the first patient in its Phase I/II trial of Sernova’s Cell Pouch for Clinical Islet Transplantation in type 1 diabetes.

“There is a real need for new treatment options in the field of type 1 diabetes,” said Dr. Piotr Witkowski, principal investigator and Director of the Pancreatic and Islet Transplant Program at University of Chicago School of Medicine. “Due to Sernova’s novel approach to demonstrate vascularization of the Cell Pouch and remarkable preclinical and first-in-human data, we are hopeful this study will provide a new functional therapeutic option in the treatment of patients with diabetes.” Dr. Witkowski added, “We expect completion of enrollment of the first patient cohort to be January 2019 and full enrollment to be completed by mid- 2019 as we continue to screen patients for the Sernova study.”

“The initiation of this Phase I/II trial is an important milestone for Sernova as our team looks to showcase our research and development efforts in diabetes on a clinical level at the University of Chicago, a world leader in regenerative medicine,” added Dr. Philip Toleikis, President and CEO of Sernova. “In our pilot first- in-human study, Sernova’s regenerative medicine approach, involving therapeutic cells within Sernova’s Cell Pouch, showed surviving vascularized islets able to produce all the hormones necessary to control blood glucose levels. Based on these positive initial results, we expect our therapeutic approach will demonstrate continued safety and therapeutic benefit to people suffering from type 1 diabetes.”

The Company is expecting to report preliminary safety data from Sernova’s clinical study in the first half of 2019 and preliminary efficacy data in the second half of 2019.

About the Study

The approved protocol is a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, where diabetic subjects with hypoglycemia unawareness enroll into the study under informed consent. Participants are then implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, is transplanted into the Cell Pouch.

A sentinel pouch will be removed for an early assessment of the islet transplant. Subjects will be followed for additional safety and efficacy measures for approximately six months. At this point, a decision will be made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will then be further followed for one year. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a series of defined measures.

For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939 . For more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova or contact (773) 702-2504.

About Diabetes

Type 1 diabetes is a chronic disease that affects more than 42.5 million globally, in which the body's immune system attacks and destroys the pancreatic cells that produce insulin, an essential hormone to help the body use glucose. To date, there is no cure for type 1 diabetes, and people living with the disease are dependent on insulin therapy, an imperfect treatment method that requires careful monitoring throughout the day along with multiple calculated doses of insulin to help regulate their blood sugar levels. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with type 1 diabetes achieve their long-term blood glucose targets, placing them at risk for type 1 diabetes- related health complications. Hypoglycemia unawareness, a subset of diabetes in which individuals experience a critical drop in blood sugar without warning symptoms, represents more than 15% of type 1 diabetes population.

About the Cell Pouch

The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long-term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

United States: Danny Matthews Solebury Trout Tel: (646) 378-2928 dmatthews@soleburytrout.com www.soleburytrout.com

For investor inquiries and media inquiries in Canada: Dominic Gray Sernova Corp Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - April 11, 2019 11 April, 2019

Sernova Announces First Transplantation of Therapeutic Cells in Cell Pouch for the Company Phase I/II U.S. Clinical Study for Diabetes

April 11, 2019, 9:00 a.m. EDT

LONDON, ONTARIO – April 11, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage regenerative medicine company today announced the first Cell Pouch™ transplant of insulin-producing cells in its U.S. Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch for Clinical Islet Transplantation in type 1 diabetes.

“Sernova’s Cell Pouch technologies are positioned to provide the most severe patients with improved, long term options to manage their diabetes,” said Dr. Piotr Witkowski, Clinical Trial Principal Investigator and Director of the Pancreatic Islet Transplant Program at the University of Chicago. “The current standard of care, involves islet transplants into the portal vein which has significant limitations including the development of an immediate blood-mediated inflammatory reaction (IBMIR), limited supply of donor organs and the challenges in isolating and obtaining a consistent quality of islet preparations.”

In accordance with the study protocol, the Cell Pouch was implanted prior to transplant of purified islets. This procedure enables the development of vascularized tissue chambers and provides an interval for patient stabilization on standard immune protection medications. Prior to transplantation, the Cell Pouch was assessed for safety. A Sentinel Pouch, a small monitoring device, was also transplanted with islets. In accordance with the protocol the Sentinel Pouch will be removed approximately 90 days post-transplant to assess islet survival as an interim indicator of efficacy.

“Sernova’s Cell Pouch provides a non-fibrosing, vascularized environment for the transplantation of therapeutic cells, to enhance the curative potential of islet transplantation and other cell therapies,” said Dr. Philip Toleikis, President and CEO of Sernova. “We are thrilled with Dr. Witkowski’s progress as well as his decision to move forward with transplantation based on his analysis of the safety and vascularization of the Cell Pouch.”

“This important clinical milestone advances our Cell Pouch technologies as a valuable enabling foundation for cell therapies across a range of indications including type 1 diabetes, hemophilia and thyroid disease,” added Dr. Toleikis.

The Company is expecting to report preliminary safety data from Sernova’s clinical study in the first half of 2019 and preliminary efficacy data in the second half of 2019.

About the Study

The approved protocol is a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, where diabetic subjects with hypoglycemia unawareness enroll into the study under informed consent. Participants are then implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, is transplanted into the Cell Pouch.

A sentinel pouch will be removed for an early assessment of the islet transplant. Subjects will be followed for additional safety and efficacy measures for approximately six months. At this point, a decision will be made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will then be further followed for one year. The primary objective of the study is to demonstrate the safety and tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a series of defined measures.

For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.

About Hypoglycemia Unawareness and Diabetes

Type 1 diabetes is a chronic disease that affects more than 42.5 million globally, in which the body's immune system attacks and destroys the pancreatic cells that produce insulin, an essential hormone to help the body use glucose. To date, there is no cure for type 1 diabetes, and people living with the disease are dependent on insulin therapy, an imperfect treatment method that requires careful monitoring throughout the day along with multiple calculated doses of insulin to help regulate their blood sugar levels. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with type 1 diabetes achieve their long-term blood glucose targets, placing them at risk for type 1 diabetes-related health complications. Hypoglycemia unawareness, a subset of diabetes in which individuals experience a critical drop in blood sugar without warning symptoms, represents more than 15% of type 1 diabetes population.

About the Cell Pouch

The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long-term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact:

United States:

Danny Matthews Solebury Trout Tel: (646) 378-2928 dmatthews@soleburytrout.com www.soleburytrout.com

Canada:

Dominic Gray Sernova Corp Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - July 03, 2019 3 July, 2019

Sernova Corp Presents Positive Preliminary Safety and Efficacy Data in its Phase I/II Clinical Trial for Type-1 Diabetes

Sernova’s Cell Pouch (TM) with transplanted islet cells reached primary safety measurements and clinically significant efficacy outcomes including glucose-stimulated C-peptide and the release of insulin in the first patient transplanted

July 3, 2019 5:30 a.m. EDT

LONDON, ONTARIO – July 3, 2019 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF), a clinical-stage regenerative medicine company today announced that in an interim analysis of its human Phase I/II clinical trial, Sernova’s Cell Pouch transplanted with islet cells showed initial safety, as well as key efficacy measures, including glucose stimulated C-peptide, insulin production and additional clinically significant measures of glucose control in the first study patient with type-1 diabetes and severe hypoglycemia unawareness.

Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago and study principal investigator presented on Sernova’s Cell Pouch technology and preliminary data from Sernova’s current clinical trial: A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch for Clinical Islet Transplantation today at the 17th World Congress of the International Pancreas and Islet Transplantation Association (IPITA) in Lyon, France.

Highlights of the presentation of the data from the first patient who received islet transplanted into Sernova Cell Pouch included:

• No incidences of adverse events determined to be related to the Cell Pouch implant.

• The Cell Pouch was well-incorporated with vascularized tissue, which enabled successful transplant of the purified islets

• A weight reduction of 6.35kg (12% total body weight)

• Stabilizing improvements in all glycemic control parameters as indicated by Continuous Glucose Monitoring (CGM) as assessed by Medtronic

• 87.5% reduction in hypoglycemic events from baseline collected over a two-week monitoring period

• Presence of stimulated blood levels of C-peptide and insulin at the observed 90-day post-transplant point as indicated in a mixed meal tolerance test

“I am quite pleased with these interim results in the first implanted patient,” said Dr. Witkowski. “The first of two doses of islets transplanted into the Cell Pouch is showing safety and early indicators of efficacy. Importantly, demonstration of glucose-stimulated C-peptide and insulin present in the bloodstream is definitive proof of islet survival and function in the Cell Pouch. These results are an important first step towards a paradigm shift in the treatment of this debilitating disease. Our team is looking forward to reporting longer- term results in enrolled patients as the trial progresses,” said Dr. Witkowski, principal study investigator.

ABOUT IPITA

The International Pancreas and Islet Transplantation Association aims to serve the pancreas and islet transplant scientific community in providing a forum for the open exchange of knowledge and expertise in order to facilitate the advancement of the clinical practice of pancreas and islet transplantation for the treatment of human diabetes.( https://www.tts.org/ipita/home)

ABOUT THE STUDY

The approved protocol is a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, where diabetic subjects with hypoglycemia unawareness enroll into the study. Participants are then implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, is transplanted into the Cell Pouch.

A sentinel pouch is removed for an early assessment of the islet transplant. Subjects will be followed for additional safety and efficacy measures for approximately six months. At this point, a decision will be made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will then be further followed for one year. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation into the Cell Pouch. The secondary objective is to assess efficacy through a series of defined measures.

For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.

ABOUT SERNOVA CORP.

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact: United States: Danny Matthews Solebury Trout Tel: (646) 378-2928 dmatthews@soleburytrout.com www.soleburytrout.com

For investor inquiries and media inquiries in Canada: Dominic Gray Sernova Corp Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778 ray@raymatthews.ca www.raymatthews.ca

FORWARD-LOOKING INFORMATION

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Press Release Communiqué de presse - October 16, 2019 16 October, 2019

Sernova Confirms Enduring Levels of Fasting C-Peptide in Bloodstream of First Patient in its Phase I/II Clinical Trial for Type-1 Diabetes

Findings further validate Cell Pouch and therapeutic cell performance in Type-1 diabetes

October 16, 2019 9:00 a.m. EDT

LONDON, ONTARIO – October 16, 2019 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical- stage regenerative medicine company, is pleased to announce the detection of enduring levels of C-peptide (measured up to 30 days and ongoing), a biomarker of transplanted beta cell insulin production, in the bloodstream of a fasting patient in its ongoing Phase I/II Cell Pouch(TM) US clinical study of type-1 diabetes. The detection of fasting C-peptide in the bloodstream of our first patient, in addition to Sernova’s recent announcement of glucose-stimulated C-peptide and other early efficacy indicators, demonstrate a normalizing response of the Cell Pouch therapeutic cells to the body’s varied need for insulin production. This is an important step forward and evidence of ongoing islet engraftment within the Cell Pouch.

“Along with the preliminary safety and early indicators of efficacy, I am excited that we are observing C-peptide levels in the patient’s bloodstream after recent transplant, not only following stimulation with a meal but also when the patient is fasting. These findings represent progress in clinical outcomes and evidence of enduring islet survival and function within Sernova’s Cell Pouch,” said Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago and study principal investigator. “We look forward to reporting ongoing results in additional patients as the trial progresses.”

The entry criteria of Sernova’s clinical study require patients to be C-peptide negative upon enrolment. C- peptide measured in the bloodstream is a biomarker of insulin and is widely used as a measure of insulin production by islet cells. C-peptide is typically measured following overnight fasting (fasting C-peptide) and during a glucose tolerance test (glucose-stimulated C-peptide). Together these measures provide an index of the patient’s ability to control blood glucose through their production of insulin.

With the goal of improved blood glucose control and stabilization of fluctuating blood sugar levels commonly experienced in people with type-1 diabetes, a normalizing response can also decrease the likelihood of life threatening hypoglycemic unaware events, a key efficacy measure in the Sernova trial.

Sernova’s clinical trial is continuing active recruitment and enrollment of study participants and further results will continue to be reported as the study progresses.

ABOUT SERNOVA’S CLINICAL TRIAL

Sernova is conducting a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, to assess the safety and tolerability of islet transplantation into the company’s patented Cell Pouch in participants with diabetes and hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures. Importantly, patients enrolled in Sernova’s clinical trial are incapable of producing C- peptide prior to implantation of Sernova’s Cell Pouch and therapeutic cells.

Eligible subjects are implanted with Cell Pouches. Following development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression and a dose of purified islets, under strict release criteria, transplanted into the Cell Pouch.

A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision is made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will be then further followed for one year to assess longer-term safety and efficacy.

For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.

ABOUT SERNOVA’S CELL POUCH

The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long- term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

ABOUT SERNOVA CORP.

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

For further information contact: Dominic Gray Sernova Corp Tel: (519) 858-5126 dominic.gray@sernova.com www.sernova.com

FORWARD-LOOKING INFORMATION This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. The information disclosed represents results from one patient and may not be representative of all study patients or of the final study results. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Dr. Philip M. Toleikis

President, CEO Président, Chef de la Direction

BA, MSc, PhD

Dr. Toleikis is currently President and Chief Executive Officer of Sernova Corp since April 2009. From 2006 until 2009, Dr. Toleikis consulted for multiple device, combination product and pharmaceutical companies. From 1996 to 2006 he held multiple roles at Angiotech Pharmaceuticals, Inc. including Vice President, Research and Development - Pharmacology and Drug Screening where he built a product development team of over 50 scientists and was responsible for multiple corporate and academic product development collaborations. M. Toleikis est actuellement président et chef de la direction de Sernova Corp depuis avril 2009. De 2006 à 2009, le Dr Toleikis a consulté plusieurs sociétés pharmaceutiques, produits combinés et produits à dispositifs multiples. De 1996 à 2006, il a occupé plusieurs postes chez Angiotech Pharmaceuticals, Inc., dont celui de vice-président, Recherche et développement - Pharmacologie et dépistage de drogues. Il a constitué une équipe de développement de produits composée de plus de 50 scientifiques et a collaboré à plusieurs

While at Sernova, Dr. Toleikis has secured over $20 million in various forms of financings, including equity raises and multiple non-dilutive grants and has been responsible for negotiating a worldwide exclusive license with UHN for its stem cell derived technologies as well as developing business relationships and or collaborations with multiple pharmaceutical and academic institutions involving its Cell Pouch™ device and cell technologies. Chez Sernova, M. Toleikis a obtenu plus de 20 millions de dollars de financements variés, y compris des levées de capitaux et de multiples subventions non dilutives, et a été responsable de la négociation d’une licence exclusive mondiale avec UHN pour ses technologies dérivées relations et / ou collaborations avec de nombreuses institutions pharmaceutiques et académiques impliquant son Cell Pouch ™ technologies des appareils et des cellules.

Dr. Toleikis is the author of multiple issued patents, over 110 patent applications, and multiple scientific publications involving transplantation, metabolic, cardiovascular, oncology, and autoimmune disease. He obtained his Ph.D. in Medicine, Pharmacology and Therapeutics from the University of British Columbia, his M.Sc. at the University of Michigan and B.A. at the University of Vermont. M. Toleikis est l'auteur de plusieurs brevets délivrés, de plus de 110 demandes de brevet et de nombreuses publications scientifiques sur la transplantation, les maladies métaboliques, cardiovasculaires, oncologiques et auto-immunes. Il a obtenu son doctorat en médecine, pharmacologie et thérapeutique de l'Université de la Colombie-Britannique, son M.Sc. à l'Université du Michigan et B.A. à l'Université du Vermont.

Among a number of volunteer activities he is a speaker at JDRF events, and a community member of UHP school council in London, Ontario. Parmi plusieurs activités de bénévolat, il est conférencier lors des événements de la FRDJ et membre communautaire du conseil scolaire UHP de London, en Ontario.

David Swetlow

Chief Financial Officer Directeur financier

David is a high tech and life sciences/biotech veteran with over 20 years in various senior management, board & advisory roles predominantly for start-up, acceleration, and high growth stage companies, including multiple companies listed on the TSX and Nasdaq such as QLT Inc., Protox Therapeutics Inc., and Xillix Technologies. David’s life sciences/biotech experience includes biopharmaceutical, medical device, and drug/device combination technologies and products. David est un vétéran de la haute technologie et des sciences de la vie et de la biotechnologie. Il compte plus de 20 ans d'expérience dans divers postes de direction, conseil et conseil, principalement pour des entreprises en phase de démarrage, d'accélération et à forte croissance, dont plusieurs sociétés cotées à la TSX et au Nasdaq, telles que QLT. Inc., Protox Therapeutics Inc. et Xillix Technologies. L’expérience de David dans le domaine des sciences de la vie et de la biotechnologie comprend des technologies et des produits biopharmaceutiques, des dispositifs médicaux et des combinaisons médicaments / dispositifs.

David holds a Bachelor of Business Administration degree from Simon Fraser University (SFU) and obtained his CA designation while at Deloitte. Entrepreneurial in nature, David has also started and run a few businesses of his own during his career. David est titulaire d'un baccalauréat en administration des affaires de l'Université Simon Fraser (SFU) et a obtenu son titre de CA chez Deloitte. De nature entrepreneuriale, David a également créé et dirigé quelques entreprises tout au long de sa carrière.

David currently sits on the Board of Directors for the Saskatchewan Science Center and is a member of its Finance, Audit & Risk Committee. Until recently, David served on the council of CMC-Saskatchewan, the provincial institute of CMC-Canada (the Canadian Association of Management Consultants), as Public Representative appointed and re-appointed for three-year terms by the Brad Wall led provincial government. David siège actuellement au conseil d'administration du Saskatchewan Science Centre et est membre de son comité des finances, de la vérification et des risques. Jusqu'à récemment, David a siégé au conseil de CMC-Saskatchewan, l'institut provincial de CMC-Canada (l'Association canadienne des conseillers en management), en tant que représentant du public nommé et renommé pour un mandat de trois ans par le gouvernement provincial dirigé par Brad Wall.

David was also previously a co-founding Director of TSX Venture company OMNItech Capital Corp. and served as Director and Audit Committee Chairman for successor companies One Person Health Sciences Inc and HealthPricer Interactive Ltd. David a également été cofondateur de OMNItech Capital Corp., société cotée à la Bourse de croissance TSX, et administrateur et président du comité d'audit pour les sociétés remplaçantes One Person Health Sciences Inc et HealthPricer Interactive Ltd.

As an active sports and outdoor enthusiast, David enjoys playing hockey, golf, skiing and outdoor-oriented activities. In the past, David also coached several boys and co-ed soccer teams and served in various executive capacities running a community-based soccer club. Passionné de sports et de plein air, David aime jouer au hockey, au golf, au ski et aux activités de plein air. Dans le passé, David a également entraîné plusieurs garçons et des équipes mixtes de football et a occupé divers postes de direction à la tête d'un club de football communautaire.

Jeffrey Bacha

Director - Board of Directors Directeur - Conseil d'administration

BSc, MBA

Jeffrey A. Bacha, BSc, MBA co-founded DelMar Pharmaceuticals in 2010 and led the company’s growth through its listing on NASDAQ in 2016 and currently serves as a member of the company's board of directors. Previously he served as the Chief Executive Officer and Chairman of the Company prior to recruiting both a seasoned independent Chair and interim Chief Executive to join the DelMar Pharmaceuticals leadership team. He is a seasoned executive leader with 20 years of life sciences experience in the areas of operations, strategy and finance for biotechnology, pharmaceutical and medical device companies in Canada, the United States and Europe. His experiences include successful public and private company building from both a start-up and turn around perspective; establishing and leading thriving management and technical teams; and raising capital in both the public and private markets. Jeffrey A. Bacha, B.Sc., MBA, a cofondé DelMar Pharmaceuticals en 2010 et a dirigé la croissance de la société grâce à son introduction au NASDAQ en 2016 et est actuellement membre du conseil d’administration de la société. Auparavant, il a été chef de la direction et président de la société avant de recruter à la fois un président indépendant et un chef de la direction par intérim pour se joindre à l'équipe de direction de DelMar Pharmaceuticals. Il est un dirigeant chevronné possédant 20 ans d’expérience en sciences de la vie dans les domaines des opérations, de la stratégie et des finances pour des sociétés de biotechnologie, pharmaceutiques et de dispositifs médicaux au Canada, aux États-Unis et en Europe. Parmi ses expériences, citons le développement réussi d'entreprises publiques et privées, à la fois dans une perspective de démarrage et de redressement; établir et diriger des équipes techniques et de gestion prospères; et lever des capitaux sur les marchés publics et privés.

From 2002 through 2005 Mr. Bacha served as President and Founding CEO of Inimex Pharmaceuticals, where he was responsible for establishing the company’s research &development team and leading venture capital financing and grant funding efforts which raised more than $35 million to support the company’s research programs. De 2002 à 2005, M. Bacha a été président et PDG fondateur d'Inimex Pharmaceuticals, où il était responsable de la mise en place de l'équipe de recherche et développement et des efforts de financement de capital-risque et de financement. .

Since 2005 until founding Del Mar Pharmaceuticals, Mr. Bacha has consulted with a number of life sciences companies and served as Executive Vice President, Corporate Affairs and Chief Operating Officer of Clera Inc. He holds an MBA from the Goizueta Business School at Emory University and a degree in BioPhysics from the University of California, San Diego. Depuis 2005 et jusqu'à la fondation de Del Mar Pharmaceuticals, M. Bacha a consulté de nombreuses entreprises du secteur des sciences de la vie et a été vice-président exécutif, affaires générales et chef de l'exploitation de Clera Inc. Il est titulaire d'un MBA de la Goizueta Business School un diplôme en bio-physique de l'Université de Californie à San Diego.

James Parsons

Director - Board of Directors Directeur - Conseil d'administration

Mr. Parsons is currently Chief Financial Officer of Trillium Therapeutics Inc. since August 2011. From 2010 to May 2013 he was Vice President Finance and Corporate Secretary at DiaMedica Therapeutics Inc. M. Parsons est actuellement chef des finances de Trillium Therapeutics Inc. depuis août 2011. De 2010 à mai 2013, il a été vice-président, finances et secrétaire général chez DiaMedica Therapeutics Inc.

Mr. Parsons has a broad background in the life sciences industry across therapeutics, diagnostics and device companies and over 25 years of financial management experience. Mr. Parsons has secured over $300 million of various forms of financing during his career and has advised and assisted on over $200 million of product licensing deals. M. Parsons a une vaste expérience dans l’industrie des sciences de la vie dans le secteur des produits thérapeutiques, des diagnostics et des appareils, et plus de 25 années d’expérience en gestion financière. M. Parsons a obtenu plus de 300 millions de dollars de diverses formes de financement au cours de sa carrière et a conseillé et aidé plus de 200 millions de dollars en contrats de licence de produits.

Mr. Parsons also serves on the board of directors of DiaMedica Therapeutics Inc. He has extensive experience in public company governance and compliance. He has a Master of Accounting degree from the University of Waterloo and is a Chartered Professional Accountant and Chartered Accountant. M. Parsons siège également au conseil d'administration de DiaMedica Therapeutics Inc. Il possède une vaste expérience en matière de gouvernance et de conformité des sociétés ouvertes. Il est titulaire d'une maîtrise en comptabilité de l'Université de Waterloo et est comptable professionnel agréé et comptable agréé.

Deborah Brown

Director - Board of Directors Directeur - Conseil d'administration

Deborah M. Brown is currently Managing Partner at Accelera Canada Ltd. Ms. Brown has extensive leadership experience with more than 20 years in senior management roles. She served as President of EMD Serono, a division of Merck KGaA, Executive Vice President at Serono US, General Manager, Director of Marketing, and Business Unit Director at Serono Canada and Manager, International Regulatory at Pasteur Merieux Connaught. Ms. Brown is a former Board Chair of Rx&D and former board member of BIOTECanada. Ms. Brown holds an MBA from Ivey School of Business. She sits on the board of several corporate and not-for-profit organizations, including Life Sciences Ontario and the Hamilton/Burlington SPCA. Deborah M. Brown est actuellement associée directrice chez Accelera Canada Ltd. Mme Brown possède une vaste expérience en leadership avec plus de 20 ans dans des rôles de direction. Elle a été présidente d'EMD Serono, une division de Merck KGaA, vice-présidente exécutive de Serono US, directrice générale, directrice du marketing et directrice de l'unité commerciale de Serono Canada et directrice, réglementation internationale de Pasteur Merieux Connaught. Mme Brown a été présidente du conseil d'administration de Rx & D et ancienne membre du conseil d'administration de BIOTECanada. Mme Brown est titulaire d'un MBA de la Ivey School of Business. Elle siège au conseil d'administration de plusieurs entreprises et organisations à but non lucratif, notamment Life Sciences Ontario et la SPCA de Hamilton / Burlington.

Frank Holler

Director and Chairman - Board of Directors Président du conseil d’administration

Mr. Holler is currently President &CEO of Ponderosa Capital Inc. Mr. Holler previously served as Chairman &CEO of BC Advantage Funds (VCC) Ltd., a venture capital firm investing in emerging technology companies in British Columbia, from 2004 to 2016; President and CEO of Xenon Pharmaceuticals Inc., a NASDAQ listed, genomics-based drug development company, from 1999 to 2003; President and CEO of ID Biomedical Corporation, a TSX/Nasdaq vaccine development company, from 1991 to 1998; and a founding director of Angiotech Pharmaceuticals, a TSX/ NASDAQ listed biotechnology company, from 1992 to 1997.                 M. Holler est actuellement président et chef de la direction de Ponderosa Capital Inc. M. Holler a déjà été président du conseil et chef de la direction de BC Advantage Funds (VCC) Ltd., une société de capital de risque investissant dans des sociétés Président et chef de la direction de Xenon Pharmaceuticals Inc., une société de développement de médicaments génomique cotée au NASDAQ, de 1999 à 2003; Président et chef de la direction de ID Biomedical Corporation, société de développement de vaccins TSX / Nasdaq, de 1991 à 1998; et administrateur fondateur d'Angiotech Pharmaceuticals, une société de biotechnologie cotée à la Bourse de Toronto / NASDAQ, de 1992 à 1997.

Prior to working in biotechnology and healthcare, Mr. Holler was a Vice-President of Investment Banking with Merrill Lynch Canada and Wood Gundy Inc. (now CIBC World Markets). In addition to serving on the Corporation’s Board, Mr. Holler presently serves on the board of directors of Xenon Pharmaceuticals and the Prevention of Organ Failure Centre at St. Pauls’s Hospital (Chairman).                 Avant de travailler dans le domaine de la biotechnologie et des soins de santé, M. Holler était vice-président des services bancaires d'investissement chez Merrill Lynch Canada et Wood Gundy Inc. (maintenant Marchés mondiaux CIBC). En plus de siéger au conseil d’administration de la société, M. Holler siège actuellement au conseil d’administration de Xenon Pharmaceuticals et du centre de prévention des défaillances des organes de l’hôpital St. Pauls (président).

Mr. Holler was previously a Director of the British Columbia Biotechnology Association from 1992 to 1998, and in 2003 received the BC Biotech Award for Vision and Leadership. He holds an MBA and BA (Economics) from the University of British Columbia. M. Holler était auparavant directeur de la British Columbia Biotechnology Association de 1992 à 1998 et, en 2003, il a reçu le prix BC Biotech pour sa vision et son leadership. Il est titulaire d'un MBA et d'un baccalauréat en économie de l'Université de la Colombie-Britannique.

Privacy PolicyPolitique de confidentialité